<html lang="en" class="pb-page js" data-request-id="94d6edbdf7276260-GRU"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6edbdf7276260-GRU">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/Bc4wwH-9WCQkYJVOaukHa6PIXE8KmxpAtynAd2KI2yXA7O4-5Pvp7iev_sxxS18DMOyeT6-Gi_vIjQbeiU1L0A=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Trial of Intravenous Immune Globulin in Dermatomyositis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6edbdf7276260-GRU">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.21915023773458375"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Inflammatory Disease|Rheumatology General|Autoimmune Disease|Neuromuscular Disease|Dermatology General|Pulmonary/Critical Care General|Allergy/Immunology General">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Allergy/Immunology|Pulmonary/Critical Care|Neurology/Neurosurgery|Rheumatology|Dermatology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2117912","title":"Trial of Intravenous Immune Globulin in Dermatomyositis","category":"Research","type":"Original Article","topics":"Inflammatory Disease|Rheumatology General|Autoimmune Disease|Neuromuscular Disease|Dermatology General|Pulmonary/Critical Care General|Allergy/Immunology General","specialties":"Allergy/Immunology|Pulmonary/Critical Care|Neurology/Neurosurgery|Rheumatology|Dermatology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-10-06T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Inflammatory Disease|Rheumatology General|Autoimmune Disease|Neuromuscular Disease|Dermatology General|Pulmonary/Critical Care General|Allergy/Immunology General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Allergy/Immunology|Pulmonary/Critical Care|Neurology/Neurosurgery|Rheumatology|Dermatology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2117912","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Trial of Intravenous Immune Globulin in Dermatomyositis","doi":"10.1056/NEJMdo006671","issueDate":"2022-10-06T00:00Z","age":"6Months-1990","isFree":"n","topics":"Inflammatory Disease|Neuromuscular Disease|Rheumatology General|Autoimmune Disease|Dermatology General|Pulmonary/Critical Care General|Allergy/Immunology General","viewType":"Full","specialties":"Rheumatology|Allergy/Immunology|Pulmonary/Critical Care|Dermatology|Neurology/Neurosurgery"},{"type":"Quick Take","title":"IVIG in Dermatomyositis","doi":"10.1056/NEJMdo006670","issueDate":"2022-10-06T00:00Z","age":"6Months-1990","isFree":"n","topics":"Inflammatory Disease|Neuromuscular Disease|Rheumatology General|Autoimmune Disease|Dermatology General|Pulmonary/Critical Care General|Allergy/Immunology General","viewType":"Full","specialties":"Rheumatology|Allergy/Immunology|Pulmonary/Critical Care|Dermatology|Neurology/Neurosurgery"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6edbdf7276260-GRU">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Trial of Intravenous Immune Globulin in Dermatomyositis"><meta name="dc.Creator" content="Rohit Aggarwal"><meta name="dc.Creator" content="Christina Charles-Schoeman"><meta name="dc.Creator" content="Joachim Schessl"><meta name="dc.Creator" content="Zsuzsanna Bata-Csörgő"><meta name="dc.Creator" content="Mazen M. Dimachkie"><meta name="dc.Creator" content="Zoltan Griger"><meta name="dc.Creator" content="Sergey Moiseev"><meta name="dc.Creator" content="Chester Oddis"><meta name="dc.Creator" content="Elena Schiopu"><meta name="dc.Creator" content="Jiri Vencovský"><meta name="dc.Creator" content="Irene Beckmann"><meta name="dc.Creator" content="Elisabeth Clodi"><meta name="dc.Creator" content="Olga Bugrova"><meta name="dc.Creator" content="Katalin Dankó"><meta name="dc.Creator" content="Floranne Ernste"><meta name="dc.Creator" content="Namita A. Goyal"><meta name="dc.Creator" content="Marvin Heuer"><meta name="dc.Creator" content="Marie Hudson"><meta name="dc.Creator" content="Yessar M. Hussain"><meta name="dc.Creator" content="Chafic Karam"><meta name="dc.Creator" content="Nina Magnolo"><meta name="dc.Creator" content="Ronald Nelson"><meta name="dc.Creator" content="Nataliia Pozur"><meta name="dc.Creator" content="Liudmyla Prystupa"><meta name="dc.Creator" content="Miklós Sárdy"><meta name="dc.Creator" content="Guillermo Valenzuela"><meta name="dc.Creator" content="Anneke J. van der Kooi"><meta name="dc.Creator" content="Tuan Vu"><meta name="dc.Creator" content="Margitta Worm"><meta name="dc.Creator" content="Todd Levine"><meta name="dc.Description" content="Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.We conducted a randomized, placebo-controlled trial involving patients with active dermato..."><meta name="Description" content="Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.We conducted a randomized, placebo-controlled trial involving patients with active dermato..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-10-06"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2117912"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202210063871408"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2209117"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2117912">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2117912">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2117912">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Trial of Intravenous Immune Globulin in Dermatomyositis | NEJM">
        <meta property="og:title" content="Trial of Intravenous Immune Globulin in Dermatomyositis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2117912">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/c2a055d2-4c89-43ea-86ad-832d0543e958/nejmoa2117912_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/c2a055d2-4c89-43ea-86ad-832d0543e958/nejmoa2117912_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been
extensively evaluated. We conducted a randomized, placebo-controlled trial involving
patients with active dermat...">
        <meta name="twitter:description" content="Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been
extensively evaluated. We conducted a randomized, placebo-controlled trial involving
patients with active dermat...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2117912">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2117912">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;issue:issue:doi\:10.1056/nejm_2022.387.issue-14;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2117912;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2117912" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2117912" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2117912" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2117912" class="inputDoi"><input type="hidden" value="R. Aggarwal and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:1264-1278" class="inputCitation"><input type="hidden" value="10-05-2022" class="inputEPubDate"><input type="hidden" value="October 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Trial of Intravenous Immune Globulin in Dermatomyositis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6edbdf7276260-GRU"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Trial of Intravenous Immune Globulin in Dermatomyositis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Rohit</span> <span property="familyName">Aggarwal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christina</span> <span property="familyName">Charles-Schoeman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joachim</span> <span property="familyName">Schessl</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zsuzsanna</span> <span property="familyName">Bata-Csörgő</span>, <span property="honorificSuffix">M.D., Dr.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mazen M.</span> <span property="familyName">Dimachkie</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zoltan</span> <span property="familyName">Griger</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sergey</span> <span property="familyName">Moiseev</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+23</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chester</span> <span property="familyName">Oddis</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elena</span> <span property="familyName">Schiopu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jiri</span> <span property="familyName">Vencovský</span>, <span property="honorificSuffix">M.D., Dr.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Irene</span> <span property="familyName">Beckmann</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elisabeth</span> <span property="familyName">Clodi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Olga</span> <span property="familyName">Bugrova</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Katalin</span> <span property="familyName">Dankó</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Floranne</span> <span property="familyName">Ernste</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Namita A.</span> <span property="familyName">Goyal</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marvin</span> <span property="familyName">Heuer</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marie</span> <span property="familyName">Hudson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yessar M.</span> <span property="familyName">Hussain</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chafic</span> <span property="familyName">Karam</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nina</span> <span property="familyName">Magnolo</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ronald</span> <span property="familyName">Nelson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nataliia</span> <span property="familyName">Pozur</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Liudmyla</span> <span property="familyName">Prystupa</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Miklós</span> <span property="familyName">Sárdy</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Guillermo</span> <span property="familyName">Valenzuela</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anneke J.</span> <span property="familyName">van der Kooi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tuan</span> <span property="familyName">Vu</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0724-0210" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0724-0210</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Margitta</span> <span property="familyName">Worm</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Todd</span> <span property="familyName">Levine</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the ProDERM Trial Group<sup><a href="#fn2" role="doc-noteref">†</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-23</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">October 5, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">1264</span>-<span property="pageEnd">1278</span></div><div class="doi">DOI: 10.1056/NEJMoa2117912</div><div class="core-enumeration"><a href="/toc/nejm/387/14"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">14</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRohit%2BAggarwal%252C%2BChristina%2BCharles-Schoeman%252C%2BJoachim%2BSchessl%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2117912%26title%3DTrial%2Bof%2BIntravenous%2BImmune%2BGlobulin%2Bin%2BDermatomyositis%26publicationDate%3D10%252F06%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2117912" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRohit%2BAggarwal%252C%2BChristina%2BCharles-Schoeman%252C%2BJoachim%2BSchessl%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2117912%26title%3DTrial%2Bof%2BIntravenous%2BImmune%2BGlobulin%2Bin%2BDermatomyositis%26publicationDate%3D10%252F06%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/56448439-f8c1-4d6a-9a08-b988e3b4055f/nejmoa2117912.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2117912.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2117912" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2117912" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2117912.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a randomized, placebo-controlled trial involving patients with active dermatomyositis. The patients were assigned in a 1:1 ratio to receive IVIG at a dose of 2.0 g per kilogram of body weight or placebo every 4 weeks for 16 weeks. The patients who received placebo and those without confirmed clinical deterioration while receiving IVIG could enter an open-label extension phase for another 24 weeks. The primary end point was a response, defined as a Total Improvement Score (TIS) of at least 20 (indicating at least minimal improvement) at week 16 and no confirmed deterioration up to week 16. <a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The TIS is a weighted composite score reflecting the change in a core set of six measures of myositis activity over time; scores range from 0 to 100, with higher scores indicating greater improvement.</span> Key secondary end points included at least moderate improvement (TIS ≥40) and major improvement (TIS ≥60), and change in score on the Cutaneous Dermatomyositis Disease Area and Severity Index.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f0.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/c2a055d2-4c89-43ea-86ad-832d0543e958/assets/images/large/nejmoa2117912_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 95 patients underwent randomization: 47 patients were assigned to the IVIG group, and 48 to the placebo group. At 16 weeks, 79% of the patients in the IVIG group (37 of 47) and 44% of those in the placebo group (21 of 48) had a TIS of at least 20 (difference, 35 percentage points; 95% confidence interval, 17 to 53; P&lt;0.001). The results with respect to the secondary end points, including at least moderate improvement and major improvement, were generally in the same direction as the results of the primary end-point analysis, except for the change in creatine kinase level (an individual core measure of the TIS), which did not differ meaningfully between the two groups. Over 40 weeks, 282 treatment-related adverse events occurred in the IVIG group, including headache (in 42% of patients), pyrexia (in 19%), and nausea (in 16%). A total of 9 serious adverse events that were considered to be related to IVIG occurred, including 6 thromboembolic events.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02728752" target="_blank">NCT02728752</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006670/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/1dfaf7c2-90e1-4137-a712-1d24f14fb520/media/NEJMdo006670_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006670/full/" class="ng-do-media_item-title-link">IVIG in Dermatomyositis</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 15s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Dermatomyositis is an uncommon systemic autoimmune disorder of unknown pathogenesis.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> The disorder in adults is characterized by chronic inflammation of the skin and muscles leading to rashes and progressive weakness, predominantly in proximal muscles.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup> Glucocorticoids are administered as first-line therapy, followed by various immunosuppressants. Intravenous immune globulin (IVIG), which is manufactured from purified liquid IgG concentrates from human plasma, has been used off-label as second- or third-line therapy for dermatomyositis, usually in combination with immunosuppressive drugs,<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4" href-manipulated="true">3,4</a></sup> and has been recommended in European guidelines as a glucocorticoid-sparing agent in patients with this disorder.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6" href-manipulated="true">5,6</a></sup> A randomized, placebo-controlled trial involving 15 patients and several noncontrolled studies have suggested that IVIG may be effective in the treatment of dermatomyositis<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r7 r8 r9 r10" id="body-ref-r10-1" href-manipulated="true">3,7–10</a></sup>; however, IVIG has been associated with thromboembolic events.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13 r14" id="body-ref-r14-1" href-manipulated="true">11-14</a></sup></div><div role="paragraph">One IVIG preparation<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> has been approved by the Food and Drug Administration, Health Canada, and the regulatory agencies in most European Union countries and the United Kingdom for the treatment of dermatomyositis. This approval was based on the results of the current Progress in Dermatomyositis (ProDERM) trial, which aimed to evaluate the efficacy and safety of this IVIG preparation in adults with dermatomyositis.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">The ProDERM trial was a prospective, phase 3, double-blind, parallel-group, randomized, placebo-controlled trial involving patients with dermatomyositis from 36 European and North American centers. Enrollment started in February 2017, and the last patient visit was in November 2019. Details of the trial design have been previously published,<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-1" href-manipulated="true" aria-label="Reference 16">16</a></sup> and the <a href="#ap1">protocol</a> is available with the full text of this article at NEJM.org.</div><div role="paragraph">The trial was designed and conducted by the sponsor, Octapharma Pharmazeutika, in collaboration with the principal investigators. The sponsor collected the data, provided the IVIG and placebo, monitored the conduct of the trial, and performed the statistical analyses. The first author prepared the initial draft of the manuscript with the support of a medical writer (funded by the sponsor). The sponsor could not delay or interdict the submission of the manuscript for publication. The authors, working under confidentiality agreements with the sponsor, had access to the data, were fully responsible for all content and editorial decisions, and approved the final version of the manuscript for submission. The authors vouch for the accuracy and completeness of the data and the reporting of adverse events and for the fidelity of the trial to the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org.</div><div role="paragraph">Written informed consent was obtained from each patient before any trial-related procedures were conducted. The trial was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation and was approved by the relevant independent ethics committees or institutional review boards, as applicable. The trial was monitored by an independent data monitoring committee.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Patients 18 to 80 years of age with definite or probable active dermatomyositis, determined according to the criteria of Bohan and Peter,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18-1" href-manipulated="true">17,18</a></sup> were eligible for the trial.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-2" href-manipulated="true" aria-label="Reference 16">16</a></sup> Patients were allowed to enter the trial if they had received previous treatment with a glucocorticoid or other immunosuppressive drug and had had either no response or an adverse event or if they were currently receiving concomitant treatment with a glucocorticoid, a maximum of two immunosuppressive drugs, or both. The maximum allowable glucocorticoid dose at trial entry was 20 mg per day of a prednisone equivalent, and the dose level at enrollment had to be maintained during the randomized, placebo-controlled phase of the trial. Concomitant treatment that was allowed in addition to glucocorticoids included a maximum of two immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, sulfasalazine, leflunomide, tacrolimus, cyclosporine, or hydroxychloroquine). These drugs were permitted if treatment had been initiated at least 3 months before enrollment and at a stable dose not exceeding the maximal allowable dose for at least 4 weeks before enrollment. Biologic agents, cyclophosphamide, IVIG, and topical glucocorticoids were not allowed; no patients received Janus kinase inhibitors. During the open-label extension phase, concomitant medication for dermatomyositis could be tapered and stopped at the treating physician’s discretion.</div><div role="paragraph">Myositis disease activity was assessed according to a core set of six measures that were designed for use in the evaluation of myositis.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r21" id="body-ref-r21" href-manipulated="true">19-21</a></sup> The core set of measures that were used as the basis for the primary end point (described below) were the Manual Muscle Test–8 (MMT-8), a measure of strength in eight muscles tested bilaterally (total scores range from 0 to 150, with lower scores indicating weaker muscles); physician’s global assessment (PhGA) of disease activity (assessed on a 10-cm visual-analogue scale, with 0 representing no evidence of disease activity and 10 extremely active or severe disease activity); patient’s global assessment (PtGA) of disease activity (assessed on the same scale as used for the PhGA of disease activity); the Health Assessment Questionnaire (HAQ, in which total scores range in increments of 0.125 from 0 [no disability] to 3 [complete disability]); extramuscular disease activity (assessed on a 10-cm visual-analogue scale on which scores range from 0 to 10, with higher scores reflecting more disease activity in the extramuscular organs affected by myositis); and serum muscle-enzyme levels (creatine kinase, alanine and aspartate aminotransferase, lactate dehydrogenase, and aldolase). Patients were eligible for enrollment if they had muscle weakness, as determined by a score of less than 142 on the MMT-8, and at least two abnormal findings on the other five core measures (a score of ≥2 on the PhGA or PtGA of disease activity or the extramuscular disease-activity measure; an HAQ total score of ≥0.25; or a muscle-enzyme level &gt;1.5 times the upper limit of the normal range). Further details of the six core-set measures are provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div><div role="paragraph">Any active rash that can be associated with dermatomyositis (heliotrope rash, Gottron’s papules, or other typical dermatomyositis rashes) was not required for inclusion; however, all the patients had a rash. The presence of active dermatomyositis was determined by an independent adjudication committee of myositis experts (see the <a href="#ap1">protocol</a>). Muscle biopsies were not performed as part of the trial. Patients with cancer-associated myositis, overlap syndromes involving myositis (except Sjögren’s syndrome), inclusion-body myositis, juvenile dermatomyositis, necrotizing myopathy, drug-induced myopathy, or polymyositis were excluded. Patients with a blood hyperviscosity or other hypercoagulable states or any history of thromboembolic events, such as deep-vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, or peripheral artery disease (Fontaine stage IV — symptoms of necrosis, gangrene of the limb, or both) were excluded. A full list of eligibility criteria is provided in the <a href="#ap1">protocol</a>. Participating institutions were requested to maintain screening logs.</div></section><section id="sec-1-3"><h3>Trial Procedures</h3><div role="paragraph">The randomized, placebo-controlled phase of the trial was from week 0 to week 16. Randomization was performed in blocks of 4 and was stratified according to the PhGA disease-activity score before enrollment (with a score of 0 to 3 indicating mild disease activity, a score of 4 to 6 moderate disease activity, and a score of 7 to 10 severe disease activity).</div><div role="paragraph">The patients were assigned in a 1:1 ratio to receive IVIG (Octagam, 10%) at a dose of 2.0 g per kilogram of body weight or placebo (0.9% sodium chloride) every 4 weeks (weeks 0, 4, 8, and 12). At each of the four infusion cycles, the total dose of IVIG or placebo was given over 2 to 5 consecutive days. If given over 2 consecutive days (the typical timing of administration), the total dose was divided into two equal doses, each of which was administered as a continuous infusion for up to 5.5 hours. At the discretion of the investigator, the number of consecutive administration days for a given infusion cycle could be increased to up to 5 days, and the total dose was divided accordingly. Infusion bags were covered with pouches to maintain blinding.</div><div role="paragraph">In the randomized, placebo-controlled phase, if a patient met published criteria for clinical deterioration (i.e., confirmed deterioration) at or after week 8 at two consecutive visits,<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r22" id="body-ref-r22" href-manipulated="true">16,22</a></sup> the patient was crossed over to the other trial group. In such event, the hospital pharmacist, who was aware of the trial-group assignments but was not involved in the direct treatment or assessment of the patients, prepared the alternate IVIG or placebo, and the trial-group assignments remained concealed from the trial personnel and patients. The criteria for clinical deterioration are listed in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph"><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-d">All patients except those who had confirmed deterioration while receiving IVIG were allowed to continue into the open-label extension phase (weeks 16 to 40), in which patients received 2.0 g per kilogram of IVIG every 4 weeks for another six infusion cycles.</span> Investigators could reduce the dose to 1.0 g per kilogram starting at week 28 if a patient’s condition was stable, as assessed by the investigator. Patients with confirmed deterioration in the extension phase were withdrawn from the trial. Given the risk of thrombosis associated with IVIG infusion<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13 r14" id="body-ref-r14-2" href-manipulated="true">11-14</a></sup> and considering that active dermatomyositis may be an additional risk factor for thromboembolism, due in part to increased inflammatory processes and decreased mobility,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24 r25 r26" id="body-ref-r26-1" href-manipulated="true">23-26</a></sup> the Wells’ probability scores for deep-vein thrombosis and pulmonary embolism were determined after each infusion in order to evaluate the risk of a thromboembolic event. If the Wells’ probability score for deep-vein thrombosis (range, –2 to 9) was at least 2 (indicating moderate or high risk), a Doppler scan of the legs was obtained, and <span data-style="small-caps">d</span>-dimer levels were measured. Treatment of suspected thromboembolic events was initiated according to local clinical practice, and the assigned trial regimen was stopped.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph"><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The primary end point was a response, which was defined as a Total Improvement Score (TIS) of at least 20 (indicating at least minimum improvement) at week 16 and no confirmed deterioration up to week 16.</span> The TIS is a weighted composite score reflecting the change in a core set of six measures of myositis activity over time; scores range from 0 to 100, with higher scores indicating greater improvement.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-4" href-manipulated="true" aria-label="Reference 16">16</a></sup> This score is calculated according to consensus 2016 American College of Rheumatology–European League against Rheumatism (ACR–EULAR) myositis response criteria for adult dermatomyositis and polymyositis.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-1" href-manipulated="true" aria-label="Reference 27">27</a></sup> At each time point, the percentage change from baseline in the absolute value for each core-set measure is calculated. On the basis of the magnitude of this percentage change, each core-set measure is allocated an “improvement score” in accordance with the ACR–EULAR response criteria, with differential weights assigned to the various core-set measures. The improvement scores for the six core-set measures are summed to provide the TIS. Because the TIS represents a change, it cannot be calculated at baseline (week 0). Further explanation of the TIS and its derivation is provided in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">There were 13 secondary efficacy end points: a response according to improvement category at week 16 (at least moderate improvement [TIS ≥40] or major improvement [TIS ≥60]); a response according to improvement category at week 40 (at least minimal improvement [TIS ≥20], at least moderate improvement, or major improvement); the mean change in scores on the modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) from baseline to week 16 (the CDASI total activity score [CDASI-A] ranges from 0 to 100, and the CDASI total damage score ranges from 0 to 32; higher scores on both indicate worse disease); the mean change in scores on the CDASI from week 16 to week 40; the mean change in quality of life, as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), from baseline to week 16; the mean change in quality of life from baseline to week 40; the mean change in individual core measures from baseline to week 16; the mean change in individual core measures from baseline to week 40; the mean TIS from baseline up to week 16; the mean TIS from baseline up to week 40; the time to at least minimal, at least moderate, and major improvement in TIS; the time to confirmed deterioration in the randomized, placebo-controlled phase and overall; and the percentage of patients in each trial group who met the criteria for clinical deterioration up to week 16.</div><div role="paragraph">Safety was assessed in all patients who received at least one dose of IVIG or placebo through 40 weeks. Adverse events, serious adverse events, and fatalities were documented throughout the trial at each visit (scheduled or unscheduled) and up to 4 weeks after the last administration of IVIG or placebo. Trial investigators assessed the causality of adverse events that occurred at their site. Adverse events were also regularly assessed by an independent data monitoring committee that also assessed all adverse events of special interest (thromboembolic events and hemolytic reactions). Trial personnel who documented adverse events were unaware of the trial-group assignments.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The trial was powered solely with respect to the primary end point. We estimated that 84 participants would be needed to provide the trial with 80% power to determine a significant difference, at an alpha level of 0.05, between the IVIG group and the placebo group in the percentage of patients who had a response, and we planned to enroll 95 patients to allow for potential dropout and to facilitate the stratified analysis. Further details of sample size and power calculations are provided in the <a href="#ap2">Supplementary Appendix</a>. Analyses of the primary efficacy end point were based on data from all the patients who underwent randomization. The last value before switching trial regimens was used in the analysis for patients who were switched to the alternate trial group. Values measured in the randomized, placebo-controlled phase after a patient had switched to the alternate trial group were excluded from the summary statistics.</div><div role="paragraph">The percentage of patients who had at least minimal improvement at week 16 (the primary end point) was compared between the trial groups with the use of the Cochran–Mantel–Haenszel test with a two-sided alpha level of 0.05 and an exact two-sided 95% confidence interval; the analysis included stratification according to the PhGA disease-activity score. A sensitivity analysis of the primary end point was performed with the use of a logistic-regression model that included the PhGA disease-activity score as a covariate. In a supportive analysis of the primary end point, differences between means were assessed with the use of the Wilcoxon–Mann–Whitney test. Changes from baseline to week 40 are presented descriptively, including unadjusted 95% confidence intervals, and no definite conclusions can be drawn from those data. Times to improvement in TIS were summarized with the use of Kaplan–Meier estimates; for the patients who crossed over to the alternate trial group, data were censored at the time of the switch. Analysis of covariance was used to analyze changes from baseline to week 16 for all continuous secondary end points, and the differences in least-squares means and the 95% confidence intervals were calculated. Because the widths of the 95% confidence intervals for secondary end points were not adjusted for multiplicity, no inferences can be drawn from these data.</div><div role="paragraph">In general, missing data were not imputed, with a few exceptions. In the analysis of covariance for the change from baseline to week 16, the last observed value was used in the main model in case of missing values (e.g., owing to early termination) and in case of a switch to the alternate trial group (because values obtained after the switch were not included in the analysis). For missing measurements of body weight, the last available body weight was used for all calculations related to dosing.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">Of 126 patients screened, 95 were enrolled: 47 were assigned to the IVIG group and 48 to the placebo group (<a href="#f1">Figure 1</a>). A total of 45 patients (96%) in the IVIG group and 46 patients (96%) in the placebo group completed the randomized, placebo-controlled phase of the trial and continued to the open-label extension phase (reasons for exclusions are given in <a href="#f1">Figure 1</a>). A total of 34 patients (72%) in the IVIG group and 35 patients (73%) in the placebo group completed the extension phase up to week 40. During the placebo-controlled phase, 5 patients in the placebo group crossed over to receive IVIG (2 patients were switched because of confirmed deterioration and 3 patients were switched in error); no patient in the IVIG group crossed over to receive placebo. Data on the primary and secondary end points were missing for 2 patients in each trial group. In total, 664 infusion cycles of IVIG were administered at a median dose of 2.0 g per kilogram over a median of 2.4 infusion days per cycle. The safety analysis during the placebo-controlled phase included 52 patients who received IVIG and 48 patients who received placebo, and the safety analysis during the open-label extension phase included 95 patients who received IVIG.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f1.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/484bb077-42ee-4171-ba4c-2aec7b1f449f/assets/images/large/nejmoa2117912_f1.jpg" height="2285" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">IVIG denotes intravenous immune globulin.</div></div></figcaption></figure></div><div role="paragraph">Demographics and other baseline characteristics were similar in the two groups (<a href="#t1">Table 1</a>). Our cohort of patients at the participating centers was generally representative of the adult population of patients with dermatomyositis; therefore, only 5% of the patients were Black (Tables S1 through S3). All the patients had symmetric proximal muscle weakness and typical skin rash, with 71% having definite dermatomyositis according to the criteria of Bohan and Peter. On the basis of the clinical features present at enrollment, 98% of the patients met the probable or definite criteria for inflammatory myopathy according to the 2017 EULAR–ACR classification criteria for idiopathic inflammatory myopathies.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> Patients had muscle weakness and active disease, with a mean MMT-8 score of 120.9 and a mean PhGA disease-activity score of 5.0. Most patients (83%) had at least mild rash (CDASI-A &gt;6), and 54% had moderate-to-severe dermatomyositis rashes (CDASI-A &gt;14). The percentage of patients with a moderate-to-severe PhGA disease activity was 77% in the IVIG group and 69% in the placebo group. The mean MMT-8 and CDASI-A scores were 121.0 and 16.6, respectively, among the patients with moderate PhGA disease activity and 102.5 and 30.6, respectively, among those with severe PhGA disease activity.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/104a710c-50d4-4795-9eac-5a4a1d760591/assets/images/large/nejmoa2117912_t1.jpg" height="3004" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Characteristics</th><th class="xxxx-borders">IVIG<br>(N=47)</th><th class="xxxx-borders">Placebo<br>(N=48)</th><th class="xxxx-borders">Total<br>(N=95)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">55.0 (22.0–77.0)</td><td class="xxxx-borders shading">51.5 (22.0–79.0)</td><td class="xxxx-borders shading">52.0 (22.0–79.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">36 (77)</td><td class="xxxx-borders">35 (73)</td><td class="xxxx-borders">71 (75)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">44 (94)</td><td class="xxxx-borders">43 (90)</td><td class="xxxx-borders">87 (92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">2 (4)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">1 (1)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Ethnic group — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Hispanic or Latino</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (10)</td><td class="xxxx-borders shading">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Not Hispanic or Latino</td><td class="xxxx-borders">47 (100)</td><td class="xxxx-borders">43 (90)</td><td class="xxxx-borders">90 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Median time since diagnosis (range) — yr</td><td class="xxxx-borders shading">2.4 (0.1–48.7)</td><td class="xxxx-borders shading">2.9 (0.1–18.4)</td><td class="xxxx-borders shading">2.6 (0.1–48.7)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Criteria of Bohan and Peter — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Symmetric proximal muscle weakness</td><td class="xxxx-borders shading">47 (100)</td><td class="xxxx-borders shading">48 (100)</td><td class="xxxx-borders shading">95 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Evidence of myositis on muscle biopsy</td><td class="xxxx-borders">23 (49)</td><td class="xxxx-borders">23 (48)</td><td class="xxxx-borders">46 (48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Elevation of serum skeletal muscle enzymes</td><td class="xxxx-borders shading">43 (91)</td><td class="xxxx-borders shading">44 (92)</td><td class="xxxx-borders shading">87 (92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Electromyographic finding consistent with myositis</td><td class="xxxx-borders">31 (66)</td><td class="xxxx-borders">26 (54)</td><td class="xxxx-borders">57 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Typical skin rash of dermatomyositis</td><td class="xxxx-borders shading">47 (100)</td><td class="xxxx-borders shading">48 (100)</td><td class="xxxx-borders shading">95 (100)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Classification of dermatomyositis according to criteria of Bohan and Peter — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Definite</td><td class="xxxx-borders shading">34 (72)</td><td class="xxxx-borders shading">33 (69)</td><td class="xxxx-borders shading">67 (71)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Probable</td><td class="xxxx-borders">13 (28)</td><td class="xxxx-borders">15 (31)</td><td class="xxxx-borders">28 (29)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Dermatomyositis activity — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Mild</td><td class="xxxx-borders">11 (23)</td><td class="xxxx-borders">15 (31)</td><td class="xxxx-borders">26 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Moderate</td><td class="xxxx-borders shading">29 (62)</td><td class="xxxx-borders shading">27 (56)</td><td class="xxxx-borders shading">56 (59)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Severe</td><td class="xxxx-borders">7 (15)</td><td class="xxxx-borders">6 (12)</td><td class="xxxx-borders">13 (14)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Concomitant medication for dermatomyositis — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Systemic glucocorticoid</td><td class="xxxx-borders">40 (85)</td><td class="xxxx-borders">44 (92)</td><td class="xxxx-borders">84 (88)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Nonglucocorticoid medication</td><td class="xxxx-borders shading">31 (66)</td><td class="xxxx-borders shading">34 (71)</td><td class="xxxx-borders shading">65 (68)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">TIS core-set measures<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Mean MMT-8 score</td><td class="xxxx-borders shading">119.5</td><td class="xxxx-borders shading">122.2</td><td class="xxxx-borders shading">120.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Mean PhGA disease-activity score</td><td class="xxxx-borders">5.13</td><td class="xxxx-borders">4.82</td><td class="xxxx-borders">4.97</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Mean PtGA disease-activity score</td><td class="xxxx-borders shading">5.86</td><td class="xxxx-borders shading">5.79</td><td class="xxxx-borders shading">5.82</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Mean HAQ total score</td><td class="xxxx-borders">1.35</td><td class="xxxx-borders">1.26</td><td class="xxxx-borders">1.31</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Mean extramuscular disease-activity score</td><td class="xxxx-borders shading">4.23</td><td class="xxxx-borders shading">4.17</td><td class="xxxx-borders shading">4.20</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Median muscle enzyme level: creatine kinase — U/liter</td><td class="xxxx-borders">141.0</td><td class="xxxx-borders">113.0</td><td class="xxxx-borders">127.0</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">IVIG denotes intravenous immune globulin.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race and ethnic group were reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">To meet the criteria of Bohan and Peter,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18-2" href-manipulated="true">17,18</a></sup> a patient must have a typical skin rash of dermatomyositis in addition to two (for probable dermatomyositis) or at least three (for definite dermatomyositis) of the following four symptoms: symmetric proximal muscle weakness, evidence of myositis on muscle biopsy, elevation of serum skeletal muscle enzyme levels, and electromyographic finding consistent with myositis.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The classification of dermatomyositis activity was based on the physician’s global assessment (PhGA) of disease activity, with a score of 0 to 3 indicating mild disease activity, 4 to 6 moderate disease activity, and 7 to 10 severe disease activity.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Concomitant therapy was allowed provided that the treatment was initiated at least 3 months before enrollment and was continued at a stable dose not exceeding the maximal allowable dose for at least 4 weeks before enrollment.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Scores on the Manual Muscle Test–8 (MMT-8), a measure of strength in eight muscles tested bilaterally, range from 0 to 150, with lower scores indicating weaker muscles. Scores on the PhGA and the patient’s global assessment (PtGA) of disease activity range from 0 (no evidence of disease activity) to 10 (extremely active or severe disease activity). Total scores on the Health Assessment Questionnaire (HAQ) range in increments of 0.125 from 0 (no disability) to 3 (complete disability). Extramuscular disease-activity scores range from 0 to 10, with higher scores reflecting more disease activity in terms of extramuscular organs affected by myositis.</div></div></div></figcaption></figure></div><div role="paragraph">The results for the other core components of the TIS were similar in the trial groups (<a href="#t1">Table 1</a>). Among the 75 patients tested for myositis-related autoantibodies, 48% had myositis-specific autoantibodies and 27% had myositis-associated autoantibodies (Table S4).</div><div role="paragraph">Overall, 99% of the patients received concomitant therapy for dermatomyositis during the trial, with 88% receiving systemic glucocorticoids and 68% receiving nonglucocorticoid medications. The use of concomitant therapy was similar in the two trial groups (<a href="#t1">Table 1</a>). Most patients had previous treatment failure with systemic glucocorticoids and at least one nonsteroidal immunosuppressive drug at or before enrollment (Table S5).</div></section><section id="sec-2-2"><h3>Primary Efficacy End Point</h3><div role="paragraph"><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b">At week 16, a response of at least minimal improvement (TIS of ≥20) was observed in 79% of the patients (37 of 47) in the IVIG group and in 44% (21 of 48) in the placebo group (adjusted difference, 35 percentage points; 95% confidence interval [CI], 16.7 to 53.2; P&lt;0.001) (<a href="#t2">Table 2</a> and Fig. S1A).</span> In a supportive analysis of the primary end point, the mean (±SD) TIS at week 16 was 47.7±24.2 in the IVIG group and 21.3±20.8 in the placebo group (mean difference, 26.4 points; 95% CI, 17.2 to 35.6). In the subgroup analysis of the TIS at week 16, in which the patients were stratified according to the PhGA disease-activity score, the percentage of patients who had a response in the IVIG group, as compared with those in the placebo group, were as follows: mild disease activity (73% vs. 27%), moderate disease activity (79% vs. 52%), and severe disease activity (86% vs. 50%); however, the trial was not powered to determine a difference in this outcome, and the analysis was not adjusted for multiplicity.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t2.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/ce167f1d-2e9d-4c3c-972e-27f6c8afd098/assets/images/large/nejmoa2117912_t2.jpg" height="3438" width="1303" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">IVIG<br>(N=47)</th><th class="txxx-borders">Placebo<br>(N=48)</th><th class="txxr-borders">Difference<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging04 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Response at week 16 — % of patients<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">79</td><td class="xxxx-borders">44</td><td class="xxxr-borders">35 (17 to 53)<a href="#t2fn3" role="doc-noteref">‡</a><a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading"><b>Secondary end point</b><a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Response according to TIS improvement category at week 16 — % of patients</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">TIS ≥40: at least moderate improvement</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">23</td><td class="xxxr-borders shading">45 (27 to 63)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">TIS ≥60: major improvement</td><td class="xxxx-borders">32</td><td class="xxxx-borders">8</td><td class="xxxr-borders">24 (8 to 39)<a href="#t2fn4" role="doc-noteref">§</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Response according to TIS improvement category at week 40 — % of patients<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">TIS ≥20: at least minimal improvement</td><td class="xxxx-borders">71</td><td class="xxxx-borders">70</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">TIS ≥40: at least moderate improvement</td><td class="xxxx-borders shading">58</td><td class="xxxx-borders shading">61</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">TIS ≥60: major improvement</td><td class="xxxx-borders">38</td><td class="xxxx-borders">30</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Modified CDASI<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in total activity score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">−9.4 (−12.5 to −6.2)</td><td class="xxxx-borders shading">−1.2 (−3.3 to 1.0)</td><td class="xxxr-borders shading">−8.0 (−11.5 to −4.6)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Week 16 to week 40</td><td class="xxxx-borders">−1.8 (−3.3 to −0.3)</td><td class="xxxx-borders">−8.5 (−12.5 to −4.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in total damage score (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−0.7 (−1.2 to −0.1)</td><td class="xxxx-borders">−0.02 (−0.26 to 0.21)</td><td class="xxxr-borders">−0.6 (−1.1 to −0.1)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Week 16 to week 40</td><td class="xxxx-borders shading">0.3 (−0.5 to 1.0)</td><td class="xxxx-borders shading">−0.2 (−0.6 to 0.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">SF-36<a href="#t2fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in physical component summary score (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">6.3 (3.6 to 9.0)</td><td class="xxxx-borders">2.4 (0.6 to 4.2)</td><td class="xxxr-borders">2.1 (−0.5 to 4.7)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">8.4 (4.3 to 12.6)</td><td class="xxxx-borders shading">6.3 (3.4 to 9.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in mental component summary score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">3.4 (1.1 to 5.6)</td><td class="xxxx-borders shading">2.0 (−0.4 to 4.3)</td><td class="xxxr-borders shading">1.4 (−1.2 to 4.1)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">4.8 (1.5 to 8.2)</td><td class="xxxx-borders">7.4 (3.9 to 10.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Individual core measures of the TIS</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in MMT-8 score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">14.4 (10.0 to 18.8)</td><td class="xxxx-borders shading">3.2 (0.3 to 6.1)</td><td class="xxxr-borders shading">8.6 (4.4 to 12.8)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">20.1 (15.0 to 25.2)</td><td class="xxxx-borders">12.0 (9.4 to 14.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in disease-activity score (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging24 shading">PhGA</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−2.4 (−3.0 to −1.8)</td><td class="xxxx-borders">−0.60 (−1.15 to −0.04)</td><td class="xxxr-borders">−1.4 (−2.1 to −0.8)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">−3.1 (−3.7 to −2.4)</td><td class="xxxx-borders shading">−2.9 (−3.6 to −2.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging24">PtGA</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">−2.2 (−2.9 to −1.5)</td><td class="xxxx-borders shading">−1.1 (−1.8 to −0.5)</td><td class="xxxr-borders shading">−1.0 (−1.8 to −0.1)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">−2.7 (−3.7 to −1.8)</td><td class="xxxx-borders">−2.8 (−3.5 to −2.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change (95% CI) in HAQ total score</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−0.6 (−0.7 to −0.4)</td><td class="xxxx-borders">−0.2 (−0.3 to −0.1)</td><td class="xxxr-borders">−0.4 (−0.5 to −0.2)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">−0.7 (−0.9 to −0.4)</td><td class="xxxx-borders shading">−0.5 (−0.7 to −0.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in extramuscular disease-activity score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">−2.2 (−2.8 to −1.5)</td><td class="xxxx-borders shading">−0.9 (−1.7 to −0.2)</td><td class="xxxr-borders shading">−1.2 (−1.9 to −0.5)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">−2.7 (−3.4 to −2.0)</td><td class="xxxx-borders">−2.6 (−3.4 to −1.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in creatine kinase level (95% CI) — U/liter<a href="#t2fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−169.2 (−301.2 to −37.2)</td><td class="xxxx-borders">−352.8 (−1011.9 to 306.3)</td><td class="xxxr-borders">−80.3 (−213.4 to 52.9)<a href="#t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">−169.4 (−326.1 to −12.7)</td><td class="xxxx-borders shading">−56.5 (−247.9 to 134.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">TIS<a href="#t2fn11" role="doc-noteref">¶¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Week 4</td><td class="xxxx-borders shading">24.4±20.8</td><td class="xxxx-borders shading">10.7±13.7</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Week 8</td><td class="xxxx-borders">36.4±21.1</td><td class="xxxx-borders">15.8±20.4</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Week 12</td><td class="xxxx-borders shading">43.4±21.9</td><td class="xxxx-borders shading">18.5±20.2</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Week 16</td><td class="xxxx-borders">48.4±24.4</td><td class="xxxx-borders">21.6±20.2</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Week 28</td><td class="xxxx-borders shading">54.0±20.0</td><td class="xxxx-borders shading">44.4±22.0</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Week 40</td><td class="xxxx-borders">55.4±21.7</td><td class="xxxx-borders">51.1±18.3</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Median time to improvement in TIS (95% CI) — days</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At least minimal improvement</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">35 (29 to 58)</td><td class="xxxx-borders shading">115 (84 to NC)<a href="#t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">35 (29 to 58)</td><td class="xxxx-borders">114 (84 to 195)</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At least moderate improvement</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">85 (58 to 113)</td><td class="xxxx-borders">NC (NC to NC)<a href="#t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">85 (58 to 113)</td><td class="xxxx-borders shading">197 (195 to 282)</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Major improvement</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">NC (115 to NC)<a href="#t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxx-borders shading">NC (NC to NC)<a href="#t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">283 (197 to 290)</td><td class="xxxx-borders">283 (203 to NC)<a href="#t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Median time to confirmed clinical deterioration in placebo-controlled phase and overall period (95% CI) — days</td><td class="xxxx-borders shading">NC<a href="#t2fn13" role="doc-noteref">***</a></td><td class="xxxx-borders shading">NC<a href="#t2fn13" role="doc-noteref">***</a></td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging04" data-xml-align="left">Patients meeting criteria for clinical deterioration up to week 16 — no. (%)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">3 (6)</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="caption">Results of Primary and Secondary Efficacy End-Point Analyses.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are means ±SD. Week 16 was the end of the double-blind, randomized, placebo-controlled phase of the trial, and week 40 was the end of the open-label extension phase. All patients received IVIG during the open-label extension phase. NA denotes not applicable, and NC not calculated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">A response was defined as a Total Improvement Score (TIS) of at least 20, indicating at least minimal improvement, at week 16. The TIS is a weighted composite score reflecting the change in a core set of six measures of myositis activity over time; scores range from 0 to 100, with higher scores indicating greater improvement from baseline (a TIS of ≥40 indicates at least moderate improvement, and a TIS of ≥60 indicates major improvement).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">P&lt;0.001 by the Cochran–Mantel–Haenszel test.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The between-group difference is expressed in percentage points.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">The widths of the 95% confidence intervals for the secondary end points have not been adjusted for multiple comparisons, and no inferences can be drawn from these data.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Improvement at week 40 was assessed among 45 patients in the IVIG group and among 46 patients in the placebo group. Conclusions cannot be drawn from the results from week 16 to week 40 (the open-label extension phase), because these results are descriptive only.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t2fn7" role="paragraph">The modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) total activity score ranges from 0 to 100, and the CDASI total damage score ranges from 0 to 32; higher scores indicate worse disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t2fn8" role="paragraph">Data are the least-squares mean difference (95% confidence interval) between IVIG and placebo at week 16.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t2fn9" role="paragraph">Physical and Mental Component Summary scores on the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) range from 0 to 100, with higher scores indicating better health status.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="t2fn10" role="paragraph">No notable changes were observed in the levels of other muscle enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and aldolase).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="t2fn11" role="paragraph">Data on the TIS were available for 45 patients in the IVIG group and for 48 patients in the placebo group at week 4. The corresponding values for the subsequent assessment weeks were 45 and 47 at week 8; 45 and 46 at week 12; 45 and 43 at week 16; 37 and 40 at week 28; and 34 and 35 at week 40.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖‖</div><div id="t2fn12" role="paragraph">NC in this cell indicates that the median time to improvement or the lower or upper limit of the 95% confidence interval was not calculated with the use of the LIFETEST procedure in the SAS statistical package (SAS Institute) because the percentage of patients with the event was too low.</div></div><div role="doc-footnote" data-has="label"><div class="label">***</div><div id="t2fn13" role="paragraph">NC in this cell indicates that the median time to confirmed clinical deterioration was not calculated with the use of the LIFETEST procedure because the percentage of patients with the event was too low.</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Secondary Efficacy End Points</h3><div role="paragraph">At week 16, a response of at least moderate improvement (TIS of ≥40) was observed in 68% of the patients (32 of 47) in the IVIG group and in 23% of the patients (11 of 48) in the placebo group, and a response of major improvement (TIS of ≥60) was observed in 32% (15 of 47) and 8% (4 of 48), respectively (<a href="#t2">Table 2</a> and Fig. S1B). <span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="one-c">At the end of the open-label extension phase (week 40), the percentage of patients who had a response of at least minimum improvement was similar in the two groups (71% of the patients [32 of 45] in the IVIG group who continued to receive IVIG in the extension phase and 70% of the patients in the placebo group who received IVIG in the extension phase) (<a href="#t2">Table 2</a> and Fig. S1C)</span>. Approximately 60% of the patients in both groups had at least moderate improvement at week 40, with more than 30% of the patients in both groups having major improvement (<a href="#t2">Table 2</a>). The results with respect to the secondary end points, including at least moderate improvement and major improvement and the mean change from baseline in the CDASI total activity score, were generally in the same direction as the results of the primary analysis (<a href="#t2">Table 2</a> and Fig. S2), with the exception of creatine kinase level, for which the 95% confidence interval included zero (<a href="#t2">Table 2</a>). The widths of 95% confidence intervals for the between-group differences in the secondary end-point analyses were not adjusted for multiple comparisons, and no definite conclusions can be drawn from these data.</div><div role="paragraph">The mean TIS at week 16 was 48.4 points in the IVIG group, and it increased further on the basis of visual inspection of graphical results up to week 40 (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2</a>). After the patients in the placebo group were switched to the IVIG regimen during the open-label extension phase, the mean TIS among them increased to a level approaching that seen in the IVIG group by week 40. <a id="exam-tint-two-c"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="two-c">The time to at least minimal improvement (TIS of ≥20) was a median 35 days in the IVIG group and 115 days in the placebo group (Fig. S3 and <a href="#t2">Table 2</a>).</span> The time to at least moderate improvement was 85 days in the IVIG group and 197 days in the placebo group, and time to major improvement was 283 days in both trial groups (<a href="#t2">Table 2</a>). The time to confirmed deterioration in the randomized, placebo-controlled phase and the open-label extension phase could not be calculated owing to the low number of patients with confirmed deterioration (<a href="#t2">Table 2</a>). During the placebo-controlled phase, clinical deterioration was confirmed in 3 patients (6%) in the placebo group and no patients in the IVIG group (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f2.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/d8e8d215-7dbb-4166-87da-a5b699acd283/assets/images/large/nejmoa2117912_f2.jpg" height="1337" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Total Improvement Score (TIS) at Week 16 and Week 40.</div><div class="notes"><div role="doc-footnote">Shown is the mean TIS up to the end of the double-blind, randomized, placebo-controlled phase at week 16 and up to the end of the open-label extension phase at week 40. The TIS is a weighted composite score reflecting the change over time in a core set of six measures of myositis activity; scores range from 0 to 100, with higher scores indicating greater improvement (see the <a href="#ap2">Supplementary Appendix</a>). Conclusions cannot be drawn from the results from week 16 to week 40 (the open-label extension phase), because these results are descriptive only. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure></div><div role="paragraph">A total of 84 patients were receiving concomitant glucocorticoids, among whom 15 (18%) were able to receive a reduced dose or discontinue the treatment during the open-label extension phase. Among the 91 patients who entered the extension phase, 8 (9%) had a reduction in the IVIG dose to 1.0 g per kilogram at or after 28 weeks.</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">In the randomized, placebo-controlled phase, 113 IVIG-related adverse events were recorded in 30 of 52 patients (58%) in the IVIG group, and 38 placebo-related adverse events were recorded in 11 of 48 patients (23%) in the placebo group (<a href="#t3">Table 3</a>). <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">During the entire trial, including the open-label extension phase, 282 treatment-related adverse events were documented with IVIG in 62 of 95 patients (65%); the most common were headache (in 42%), pyrexia (in 19%), and nausea (in 16%) (<a href="#t3">Table 3</a>). Most treatment-related adverse events occurred during or within 72 hours after the end of an infusion cycle (in 92% [260 events]) and were mild (in 73.4% [207 events]), moderate (in 23.4% [66 events]), or severe (in 3.2% [9 events]).</span> During the randomized, placebo-controlled phase, 5 serious adverse events occurred after an IVIG infusion in 3 patients (6%) (sepsis and pulmonary embolism in 1 patient, muscle spasm and dyspnea in 1 patient, and ventricular extrasystoles in 1 patient), and 4 serious adverse events occurred after a placebo infusion in 2 patients (4%) (tropical spastic paresis in 1 patient and hypertension and two episodes of sinus tachycardia in 1 patient). Overall, 9 serious treatment-related adverse events occurred among 7 patients during both phases of the trial (<a href="#t3">Table 3</a>). <a id="exam-tint-two-a"></a><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="two-a">No deaths and no hemolytic transfusion reactions were reported during the trial.</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t3.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/3acf58d8-7c48-4c6d-8300-33445439b081/assets/images/large/nejmoa2117912_t3.jpg" height="2073" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="2"><span>Randomized,<br>Placebo-Controlled Phase</span></th><th class="txxr-borders">Randomized and Open-Label Extension Phases</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">IVIG<br>(N=52)</th><th class="xxxx-borders">Placebo<br>(N=48)</th><th class="xxxr-borders">IVIG<br>(N=95)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any related adverse event — % of patients (no. of events)</td><td class="xxxx-borders shading">58 (113)</td><td class="xxxx-borders shading">23 (38)</td><td class="xxxr-borders shading">65 (282)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Most frequent related adverse event occurring in ≥5% of patients — % of patients</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">6</td><td class="xxxr-borders shading">42</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">19</td><td class="xxxx-borders">6</td><td class="xxxr-borders">19</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">4</td><td class="xxxr-borders shading">16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0</td><td class="xxxr-borders">8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chills</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">2</td><td class="xxxr-borders shading">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Myalgia</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0</td><td class="xxxr-borders">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">6</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Positive Coombs’ test</td><td class="xxxx-borders">4</td><td class="xxxx-borders">0</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious related nonthromboembolic adverse event — no. of patients/no. of events</td><td class="xxxx-borders shading">1/2</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2/3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Muscle spasm</td><td class="xxxx-borders">1/1<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1<a href="#t3fn1" role="doc-noteref">*</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dyspnea</td><td class="xxxx-borders shading">1/1<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1<a href="#t3fn1" role="doc-noteref">*</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Loss of consciousness</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious related thromboembolic adverse event — no. of patients/no. of events</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">5/6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Deep-vein thrombosis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1<a href="#t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pulmonary embolism</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1<a href="#t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cerebrovascular accident</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cerebral infarction</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypoesthesia</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pulmonary embolism</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Related adverse events leading to discontinuation — % of patients (no. of events)</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">8 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Fatal adverse events — no. of events</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="caption">Incidence of Adverse Events That Were Considered to Be Related to the Trial Regimen during the Placebo-Controlled and Extension Phases.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Muscle spasm and dyspnea were two concurrent events in 1 patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Deep-vein thrombosis and pulmonary embolism were two concurrent events in 1 patient and thus were counted as one thromboembolic adverse event.</div></div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-two-d"></a><span id="tint9" class="named-content" data-type="exam-tint" data-answer-ids="two-d">Because dermatomyositis (which is associated with decreased mobility and increased inflammatory processes)<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24 r25 r26" id="body-ref-r26-2" href-manipulated="true">23-26</a></sup> and treatment with IVIG<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13 r14" id="body-ref-r14-3" href-manipulated="true">11-14</a></sup> are both considered to be risk factors for thromboembolic events, emphasis was placed on monitoring for these events. During the entire trial, 8 thromboembolic events were documented among 6 patients who received treatment with IVIG. A total of 6 thromboembolic events that were considered to be related to the trial regimen occurred among 5 patients, which led to an amendment to the trial protocol in July 2018 in which the maximum allowable infusion rate was reduced from 0.12 to 0.04 ml per kilogram per minute.</span> A total of 59 patients were enrolled before and 36 patients were enrolled after amendment. The incidence of thromboembolic events was 1.54 per 100 patient-months before and 0.54 per 100 patient-months after amendment.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the 16-week randomized, placebo-controlled phase of the trial, the percentage of patients who had a response of at least minimal improvement at week 16 was significantly higher among the patients who received IVIG than among those who received placebo. <a id="exam-tint-two-b"></a><span id="tint10" class="named-content" data-type="exam-tint" data-answer-ids="two-b">The percentage of patients who had a response of at least moderate improvement or a response of major improvement was greater with IVIG than with placebo, but the 95% confidence intervals for the between-group differences in these end points were not adjusted for multiple comparisons.</span> The median time to at least minimal improvement was 35 days with IVIG and 115 days with placebo. The results of the other secondary end-point analyses were also generally in the same direction as the results of the primary efficacy analysis, including muscle strength and skin rash. Creatine kinase levels varied among the patients in the trial groups; however, there was no appreciable between-group difference in the change from baseline in creatine kinase level at week 16. The efficacy of IVIG with respect to the primary end point was observed among the patients across mild, moderate, and severe disease-activity categories.</div><div role="paragraph">Two previous double-blind, placebo-controlled trials investigating the efficacy of IVIG among patients with dermatomyositis were small but provided preliminary evidence of efficacy and safety.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r29" id="body-ref-r29-1" href-manipulated="true">10,29</a></sup> One of the trials showed that IVIG, as compared with placebo, improved muscle strength and reduced neuromuscular symptoms.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-3" href-manipulated="true" aria-label="Reference 10">10</a></sup> In contrast, in the other trial involving patients with glucocorticoid-resistant polymyositis and dermatomyositis, muscle strength improved similarly in the IVIG group and placebo group.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29-2" href-manipulated="true" aria-label="Reference 29">29</a></sup> In addition, a number of noncontrolled studies have shown that IVIG reduces symptoms of dermatomyositis.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r7 r8 r9" id="body-ref-r9-2" href-manipulated="true">3,7–9</a></sup></div><div role="paragraph">The current trial permitted concomitant therapy in parallel with the trial treatment, and 88% of patients were receiving concomitant glucocorticoids; one patient was not receiving concomitant medication for dermatomyositis at trial entry but had had previous treatment failure with a glucocorticoid and other immunosuppressive drugs. Approximately 20% of the patients who were receiving concomitant glucocorticoids were able to receive a reduced dose or discontinue the treatment during the open-label extension phase of the trial, but no conclusions can be made regarding a potential glucocorticoid-sparing effect of IVIG. Dose reduction was initiated at the physician’s discretion and was not stipulated by the protocol; it is plausible that the percentage of patients who had a dose reduction may have been different if the decision had been patient-driven.</div><div role="paragraph">Most adverse events were reported during or within 72 hours after the IVIG infusion and were mild. Headache was common but was rated as mild in 75% of instances because the events were transient or did not interfere with routine activities; no premedications were used to mitigate these side effects of IVIG infusion unless they occurred in two consecutive cycles. Dermatomyositis and IVIG administration are risk factors for thromboembolic events,<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13 r14 r23 r24 r25 r26" id="body-ref-r26-3" href-manipulated="true">11–14,23–26</a></sup> and we emphasized monitoring for these events. Eight patients in the IVIG group discontinued IVIG because of adverse events, including six thromboembolic events in five patients, that were considered to be related to the trial regimen. After the first thromboembolic events of the trial were adjudicated, the protocol was modified to reduce the maximum infusion rate of IVIG, which led to a reduction in the incidence of thromboembolic events. No events of IVIG-related hemolytic anemia were reported during the trial.</div><div role="paragraph">The mechanism of action of IVIG in patients with dermatomyositis is not understood but may involve inhibition of complement consumption and interference with formation of the membrane attack complex.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r31" id="body-ref-r31-1" href-manipulated="true">30,31</a></sup> These actions have been implicated in dermatomyositis and are considered to be pertinent because there is C3 activation in this condition, leading to formation and deposition of membrane attack complex on endomysial capillaries and subsequent capillary destruction resulting in microangiopathy; however, the relation between these actions and clinical changes in patients with dermatomyositis remains to be determined.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32 r33 r34 r35" id="body-ref-r35" href-manipulated="true">32-35</a></sup> In addition, IVIG may lead to down-regulation of cytokines and chemokines<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30-2" href-manipulated="true" aria-label="Reference 30">30</a></sup> and modification of gene expression<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31-2" href-manipulated="true" aria-label="Reference 31">31</a></sup> in patients with dermatomyositis.</div><div role="paragraph">Our trial has several limitations. The duration of the randomized, placebo-controlled phase of the trial was brief at 16 weeks, and patients with juvenile, cancer-associated, or amyopathic dermatomyositis were excluded. The primary end point of the trial was based on the TIS, a composite response score approved by the ACR–EULAR that was developed and validated in accordance with a data-driven approach that was followed by consensus among rheumatologists, neurologists, and dermatologists.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r27 r36 r37" id="body-ref-r37" href-manipulated="true">19,27,36,37</a></sup> The TIS has been used as the primary end point in smaller studies.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38 r39" id="body-ref-r39" href-manipulated="true">38,39</a></sup> Training and experience are needed to acquire the scores for the core-set measures and to interpret the results. Because myositis autoantibodies were not systematically collected, we could not assess the effect of IVIG according to autoantibody subsets. The response rate in the placebo group was high, which may have been caused by the low threshold set for the achievement of minimal improvement, background immunosuppression, and the subjective nature of some end-point measures, such as the PhGA and PtGA of disease activity. A further limitation is that three patients in the placebo group were switched to the IVIG group on account of procedural errors; however, a sensitivity analysis showed that these errors did not affect the primary results of the trial.</div><div role="paragraph">In this 16-week, randomized, controlled trial of four infusion cycles of IVIG, the percentage of patients with dermatomyositis who had at least minimal improvement according to a composite score of disease activity was significantly greater with IVIG than with placebo; however, IVIG was associated with adverse infusion events and thromboembolism. Larger and longer trials to determine the long-term effects and risks of IVIG in patients with dermatomyositis are warranted.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Octapharma Pharmazeutika</span>. Dr. Vencovský’s work in myositis is supported by grant 00023728 from the Czech Ministry of Health (Project for Conceptual Development of Research Organization [Institute of Rheumatology]).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the investigators, trial personnel, and patients for their participation; Kat Karolemeas from Nspm, Meggen, Switzerland, for medical writing assistance (funded by Octapharma Pharmazeutika, Vienna); Andreas Laurenz Trawnicek from Octapharma Pharmazeutika, who led the statistical analyses; and Ali Ciersdorf, Lucy Lam, Brittany Harvey, and Diane Koontz, who acted as trial coordinators at some of the authors’ centers.</div><div role="paragraph">This article is dedicated to the memory of Dr. Katalin Dankó for her contribution to the field of myositis.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2117912_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2117912/suppl_file/nejmoa2117912_research-summary.pdf" download="nejmoa2117912_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2117912_research-summary.pdf" data-doi="10.1056/NEJMoa2117912">Download</a></li><li>728.10 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2117912_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2117912/suppl_file/nejmoa2117912_protocol.pdf" download="nejmoa2117912_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2117912_protocol.pdf" data-doi="10.1056/NEJMoa2117912">Download</a></li><li>3.82 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2117912_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2117912/suppl_file/nejmoa2117912_appendix.pdf" download="nejmoa2117912_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2117912_appendix.pdf" data-doi="10.1056/NEJMoa2117912">Download</a></li><li>442.24 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2117912_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2117912/suppl_file/nejmoa2117912_disclosures.pdf" download="nejmoa2117912_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2117912_disclosures.pdf" data-doi="10.1056/NEJMoa2117912">Download</a></li><li>1.22 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2117912_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2117912/suppl_file/nejmoa2117912_data-sharing.pdf" download="nejmoa2117912_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2117912_data-sharing.pdf" data-doi="10.1056/NEJMoa2117912">Download</a></li><li>69.96 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Dalakas MC. Inflammatory muscle diseases. <em>N Engl J Med</em> 2015;372:1734-1747.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJMra1402225&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25923553/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000353655000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inflammatory+muscle+diseases.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1734-1747&amp;doi=10.1056%2FNEJMra1402225&amp;pmid=25923553" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disorder of unknown pathogenesis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] predominantly in proximal muscles. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Oddis CV, Aggarwal R. Treatment in myositis. <em>Nat Rev Rheumatol</em> 2018;14:279-289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrrheum.2018.42" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29593343/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430747200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+in+myositis.&amp;publication_year=2018&amp;journal=Nat+Rev+Rheumatol&amp;pages=279-289&amp;doi=10.1038%2Fnrrheum.2018.42&amp;pmid=29593343" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. <em>Autoimmun Rev</em> 2009;9:124-127.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.autrev.2009.04.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19386287/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272277100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+immunoglobulin+as+add+on+treatment+with+mycophenolate+mofetil+in+severe+myositis.&amp;publication_year=2009&amp;journal=Autoimmun+Rev&amp;pages=124-127&amp;doi=10.1016%2Fj.autrev.2009.04.003&amp;pmid=19386287" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] combination with immunosuppressive drugs, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Ho C, Visintini S. Off-label use of intravenous immunoglobulin for dermatological conditions: a review of clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health, April 20, 2018 (<a href="https://www.cadth.ca/sites/default/files/pdf/htis/2018/RC0965%20-%20Off-label%20IVIG%20Final.pdf">https://www.cadth.ca/sites/default/files/pdf/htis/2018/RC0965%20-%20Off-label%20IVIG%20Final.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Off-label+use+of+intravenous+immunoglobulin+for+dermatological+conditions%3A+a+review+of+clinical+effectiveness&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. <em>Eur J Neurol</em> 2008;15:893-908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-1331.2008.02246.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18796075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258355900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EFNS+guidelines+for+the+use+of+intravenous+immunoglobulin+in+treatment+of+neurological+diseases%3A+EFNS+task+force+on+the+use+of+intravenous+immunoglobulin+in+treatment+of+neurological+diseases.&amp;publication_year=2008&amp;journal=Eur+J+Neurol&amp;pages=893-908&amp;doi=10.1111%2Fj.1468-1331.2008.02246.x&amp;pmid=18796075" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. <em>Eur J Dermatol</em> 2009;19:90-98.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1684/ejd.2008.0580" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19171549/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263100300031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+on+the+use+of+high-dose+intravenous+immunoglobulin+in+dermatology.&amp;publication_year=2009&amp;journal=Eur+J+Dermatol&amp;pages=90-98&amp;doi=10.1684%2Fejd.2008.0580&amp;pmid=19171549" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. <em>Am J Med</em> 1991;91:162-168.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0002-9343(91)90009-M" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1714235/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1991GB07200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+intravenous+gammaglobulin+therapy+in+chronic+refractory+polymyositis+and+dermatomyositis%3A+an+open+study+with+20+adult+patients.&amp;publication_year=1991&amp;journal=Am+J+Med&amp;pages=162-168&amp;doi=10.1016%2F0002-9343%2891%2990009-M&amp;pmid=1714235" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. <em>J Neurol Neurosurg Psychiatry</em> 1998;65:107-110.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp.65.1.107" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9667570/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000074643100018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immunoglobulin+therapy+in+inflammatory+myopathies.&amp;publication_year=1998&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=107-110&amp;doi=10.1136%2Fjnnp.65.1.107&amp;pmid=9667570" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. <em>Mod Rheumatol</em> 2008;18:34-44.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/s10165-007-0013-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18217197/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264090600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+high-dose+intravenous+immunoglobulin+therapy+in+Japanese+patients+with+steroid-resistant+polymyositis+and+dermatomyositis.&amp;publication_year=2008&amp;journal=Mod+Rheumatol&amp;pages=34-44&amp;doi=10.3109%2Fs10165-007-0013-0&amp;pmid=18217197" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. <em>N Engl J Med</em> 1993;329:1993-2000.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM199312303292704&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8247075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1993MN57300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+high-dose+intravenous+immune+globulin+infusions+as+treatment+for+dermatomyositis.&amp;publication_year=1993&amp;journal=N+Engl+J+Med&amp;pages=1993-2000&amp;doi=10.1056%2FNEJM199312303292704&amp;pmid=8247075" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] evidence of efficacy and safety. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and reduced neuromuscular symptoms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. <em>Blood Coagul Fibrinolysis</em> 2005;16:313-318.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/01.mbc.0000172694.85233.a8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15970713/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000231054300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Venous+and+arterial+thrombosis+following+administration+of+intravenous+immunoglobulins.&amp;publication_year=2005&amp;journal=Blood+Coagul+Fibrinolysis&amp;pages=313-318&amp;doi=10.1097%2F01.mbc.0000172694.85233.a8&amp;pmid=15970713" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Marie I, Maurey G, Hervé F, Hellot M-F, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature. <em>Br J Dermatol</em> 2006;155:714-721.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2133.2006.07390.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16965420/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240348900010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+immunoglobulin-associated+arterial+and+venous+thrombosis%3A+report+of+a+series+and+review+of+the+literature.&amp;publication_year=2006&amp;journal=Br+J+Dermatol&amp;pages=714-721&amp;doi=10.1111%2Fj.1365-2133.2006.07390.x&amp;pmid=16965420" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. <em>Expert Opin Drug Saf</em> 2010;9:971-979.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1517/14740338.2010.484419" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20408737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282970700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+of+intravenous+immunoglobulin+treatment.&amp;publication_year=2010&amp;journal=Expert+Opin+Drug+Saf&amp;pages=971-979&amp;doi=10.1517%2F14740338.2010.484419&amp;pmid=20408737" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Kapoor M, Hunt I, Spillane J, et al. IVIg-exposure and thromboembolic event risk: findings from the UK Biobank. <em>J Neurol Neurosurg Psychiatry</em> 2022;93:876-885.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2022-328881" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35688633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000810553900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IVIg-exposure+and+thromboembolic+event+risk%3A+findings+from+the+UK+Biobank.&amp;publication_year=2022&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=876-885&amp;doi=10.1136%2Fjnnp-2022-328881&amp;pmid=35688633" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Chandra T, Aggarwal R. Clinical trials and novel therapeutics in dermatomyositis. <em>Expert Opin Emerg Drugs</em> 2020;25:213-228.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/14728214.2020.1787985" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32597690/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000547133100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+trials+and+novel+therapeutics+in+dermatomyositis.&amp;publication_year=2020&amp;journal=Expert+Opin+Emerg+Drugs&amp;pages=213-228&amp;doi=10.1080%2F14728214.2020.1787985&amp;pmid=32597690" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”). <em>Medicine (Baltimore)</em> 2021;100(1):e23677-e23677.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MD.0000000000023677" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33429735/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000612794500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prospective%2C+double-blind%2C+randomized%2C+placebo-controlled+phase+III+study+evaluating+efficacy+and+safety+of+octagam+10%25+in+patients+with+dermatomyositis+%28%E2%80%9CProDERM+Study%E2%80%9D%29.&amp;publication_year=2021&amp;journal=Medicine+%28Baltimore%29&amp;pages=e23677-e23677&amp;doi=10.1097%2FMD.0000000000023677&amp;pmid=33429735" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] design have been previously published, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were eligible for the trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] or after week 8 at two consecutive visits, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] scores indicating greater improvement. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Bohan A, Peter JB. Polymyositis and dermatomyositis — (second of two parts). <em>N Engl J Med</em> 1975;292:403-407.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM197502202920807&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1089199/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1975V574800007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Polymyositis+and+dermatomyositis+%E2%80%94+%28second+of+two+parts%29.&amp;publication_year=1975&amp;journal=N+Engl+J+Med&amp;pages=403-407&amp;doi=10.1056%2FNEJM197502202920807&amp;pmid=1089199" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to the criteria of Bohan and Peter, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r17-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] To meet the criteria of Bohan and Peter, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Bohan A, Peter JB. Polymyositis and dermatomyositis — (first of two parts). <em>N Engl J Med</em> 1975;292:344-347.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM197502132920706&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1090839/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1975V510400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Polymyositis+and+dermatomyositis+%E2%80%94+%28first+of+two+parts%29.&amp;publication_year=1975&amp;journal=N+Engl+J+Med&amp;pages=344-347&amp;doi=10.1056%2FNEJM197502132920706&amp;pmid=1090839" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to the criteria of Bohan and Peter, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r18-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] To meet the criteria of Bohan and Peter, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. <em>Arthritis Rheum</em> 2004;50:2281-2290.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.20349" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15248228/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+consensus+on+preliminary+definitions+of+improvement+in+adult+and+juvenile+myositis.&amp;publication_year=2004&amp;journal=Arthritis+Rheum&amp;pages=2281-2290&amp;doi=10.1002%2Fart.20349&amp;pmid=15248228" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for use in the evaluation of myositis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] neurologists, and dermatologists. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Rider LG, Aggarwal R, Machado PM, et al. Update on outcome assessment in myositis. <em>Nat Rev Rheumatol</em> 2018;14:303-318.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrrheum.2018.33" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29651119/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430747200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+outcome+assessment+in+myositis.&amp;publication_year=2018&amp;journal=Nat+Rev+Rheumatol&amp;pages=303-318&amp;doi=10.1038%2Fnrrheum.2018.33&amp;pmid=29651119" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. <em>Rheumatology (Oxford)</em> 2001;40:1262-1273.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/40.11.1262" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11709610/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000172378500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Proposed+preliminary+core+set+measures+for+disease+outcome+assessment+in+adult+and+juvenile+idiopathic+inflammatory+myopathies.&amp;publication_year=2001&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1262-1273&amp;doi=10.1093%2Frheumatology%2F40.11.1262&amp;pmid=11709610" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. <em>Arthritis Rheum</em> 2013;65:314-324.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.37754" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23124935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000314169400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+in+the+treatment+of+refractory+adult+and+juvenile+dermatomyositis+and+adult+polymyositis%3A+a+randomized%2C+placebo-phase+trial.&amp;publication_year=2013&amp;journal=Arthritis+Rheum&amp;pages=314-324&amp;doi=10.1002%2Fart.37754&amp;pmid=23124935" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Selva-O’Callaghan A, Fernández-Luque A, Martínez-Gómez X, Labirua-Iturburu A, Vilardell-Tarrés M. Venous thromboembolism in patients with dermatomyositis and polymyositis. <em>Clin Exp Rheumatol</em> 2011;29:846-849.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21962007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297192600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Venous+thromboembolism+in+patients+with+dermatomyositis+and+polymyositis.&amp;publication_year=2011&amp;journal=Clin+Exp+Rheumatol&amp;pages=846-849&amp;pmid=21962007" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Antovic A, Notarnicola A, Svensson J, Lundberg IE, Holmqvist M. Venous thromboembolic events in idiopathic inflammatory myopathy: occurrence and relation to disease onset. <em>Arthritis Care Res (Hoboken)</em> 2018;70:1849-1855.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.23560" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29579357/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451429400017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Venous+thromboembolic+events+in+idiopathic+inflammatory+myopathy%3A+occurrence+and+relation+to+disease+onset.&amp;publication_year=2018&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=1849-1855&amp;doi=10.1002%2Facr.23560&amp;pmid=29579357" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. <em>Ann Rheum Dis</em> 2016;75:110-116.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2014-205800" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25193998/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366402400011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+deep+venous+thrombosis+and+pulmonary+embolism+in+individuals+with+polymyositis+and+dermatomyositis%3A+a+general+population-based+study.&amp;publication_year=2016&amp;journal=Ann+Rheum+Dis&amp;pages=110-116&amp;doi=10.1136%2Fannrheumdis-2014-205800&amp;pmid=25193998" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Chung W-S, Lin C-L, Sung F-C, Lu C-C, Kao C-H. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. <em>Thromb Res</em> 2014;134:622-626.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r26" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.thromres.2014.06.021" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25034321/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341310000018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+risk+of+venous+thromboembolism+in+patients+with+dermatomyositis%2Fpolymyositis%3A+a+nationwide+cohort+study.&amp;publication_year=2014&amp;journal=Thromb+Res&amp;pages=622-626&amp;doi=10.1016%2Fj.thromres.2014.06.021&amp;pmid=25034321" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r26" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. <em>Arthritis Rheumatol</em> 2017;69:898-910.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40064" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28382787/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2016+American+College+of+Rheumatology%2FEuropean+League+Against+Rheumatism+criteria+for+minimal%2C+moderate%2C+and+major+clinical+response+in+adult+dermatomyositis+and+polymyositis%3A+an+international+myositis+assessment+and+clinical+studies+group%2Fpaediatric+rheumatology+international+trials+organisation+collaborative+initiative.&amp;publication_year=2017&amp;journal=Arthritis+Rheumatol&amp;pages=898-910&amp;doi=10.1002%2Fart.40064&amp;pmid=28382787" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for adult dermatomyositis and polymyositis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] neurologists, and dermatologists. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <em>Arthritis Rheumatol</em> 2017;69:2271-2282.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40320" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29106061/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2017+European+League+Against+Rheumatism%2FAmerican+College+of+Rheumatology+classification+criteria+for+adult+and+juvenile+idiopathic+inflammatory+myopathies+and+their+major+subgroups.&amp;publication_year=2017&amp;journal=Arthritis+Rheumatol&amp;pages=2271-2282&amp;doi=10.1002%2Fart.40320&amp;pmid=29106061" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. <em>Mod Rheumatol</em> 2012;22:382-393.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/s10165-011-0534-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21971943/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305275300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+intravenous+immunoglobulin+therapy+in+Japanese+patients+with+polymyositis+and+dermatomyositis+resistant+to+corticosteroids%3A+a+randomized+double-blind+placebo-controlled+trial.&amp;publication_year=2012&amp;journal=Mod+Rheumatol&amp;pages=382-393&amp;doi=10.3109%2Fs10165-011-0534-4&amp;pmid=21971943" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] evidence of efficacy and safety. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the IVIG group and placebo group. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. <em>J Clin Immunol</em> 2014;34:Suppl 1:S120-S126.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10875-014-0024-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24722854/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanistic+effects+of+IVIg+in+neuroinflammatory+diseases%3A+conclusions+based+on+clinicopathologic+correlations.&amp;publication_year=2014&amp;journal=J+Clin+Immunol&amp;pages=S120-S126&amp;doi=10.1007%2Fs10875-014-0024-5&amp;pmid=24722854" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r31-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] formation of the membrane attack complex. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] down-regulation of cytokines and chemokines </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. <em>Curr Rheumatol Rep</em> 2011;13:192-198.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r31" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11926-011-0171-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21503696/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000208771200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanisms+of+action+of+intravenous+immunoglobulin+in+inflammatory+muscle+disease.&amp;publication_year=2011&amp;journal=Curr+Rheumatol+Rep&amp;pages=192-198&amp;doi=10.1007%2Fs11926-011-0171-0&amp;pmid=21503696" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r31" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r31-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] formation of the membrane attack complex. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and modification of gene expression </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Basta M, Van Goor F, Luccioli S, et al. F(ab)’2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. <em>Nat Med</em> 2003;9:431-438.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm836" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12612546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000181987400033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=F%28ab%29%E2%80%992-mediated+neutralization+of+C3a+and+C5a+anaphylatoxins%3A+a+novel+effector+function+of+immunoglobulins.&amp;publication_year=2003&amp;journal=Nat+Med&amp;pages=431-438&amp;doi=10.1038%2Fnm836&amp;pmid=12612546" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. <em>J Clin Invest</em> 1994;94:1729-1735.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI117520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7962520/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PQ94100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+intravenous+immunoglobulin+exerts+its+beneficial+effect+in+patients+with+dermatomyositis+by+blocking+endomysial+deposition+of+activated+complement+fragments.&amp;publication_year=1994&amp;journal=J+Clin+Invest&amp;pages=1729-1735&amp;doi=10.1172%2FJCI117520&amp;pmid=7962520" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. <em>Ann Neurol</em> 1990;27:343-356.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.410270402" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2353792/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1990CZ77200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Microvascular+changes+in+early+and+advanced+dermatomyositis%3A+a+quantitative+study.&amp;publication_year=1990&amp;journal=Ann+Neurol&amp;pages=343-356&amp;doi=10.1002%2Fana.410270402&amp;pmid=2353792" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. <em>N Engl J Med</em> 1986;314:329-334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_36_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM198602063140601&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/3945256/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1986AYS4600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Microvascular+deposition+of+complement+membrane+attack+complex+in+dermatomyositis.&amp;publication_year=1986&amp;journal=N+Engl+J+Med&amp;pages=329-334&amp;doi=10.1056%2FNEJM198602063140601&amp;pmid=3945256" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <em>Arthritis Care Res (Hoboken)</em> 2010;62:1533-1541.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20280" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20583105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000284041200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+Paediatric+Rheumatology+International+Trials+Organisation+provisional+criteria+for+the+evaluation+of+response+to+therapy+in+juvenile+dermatomyositis.&amp;publication_year=2010&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=1533-1541&amp;doi=10.1002%2Facr.20280&amp;pmid=20583105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Rider LG, Giannini EH, Harris-Love M, et al. Defining clinical improvement in adult and juvenile myositis. <em>J Rheumatol</em> 2003;30:603-617.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12610824/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+clinical+improvement+in+adult+and+juvenile+myositis.&amp;publication_year=2003&amp;journal=J+Rheumatol&amp;pages=603-617&amp;pmid=12610824" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. <em>Rheumatology (Oxford)</em> 2021;60:1784-1792.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keaa459" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33099648/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000644544400040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+immunoglobulins+as+first-line+treatment+in+idiopathic+inflammatory+myopathies%3A+a+pilot+study.&amp;publication_year=2021&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1784-1792&amp;doi=10.1093%2Frheumatology%2Fkeaa459&amp;pmid=33099648" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. <em>Arthritis Rheumatol</em> 2021;73:858-865.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41602" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33258553/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Study+of+tofacitinib+in+refractory+dermatomyositis%3A+an+open-label+pilot+study+of+ten+patients.&amp;publication_year=2021&amp;journal=Arthritis+Rheumatol&amp;pages=858-865&amp;doi=10.1002%2Fart.41602&amp;pmid=33258553" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/14"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">14</span></span> • <span property="datePublished">October 6, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1264</span>-<span property="pageEnd">1278</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: October 5, 2022</div><div><b class="core-label">Published in issue</b>: October 6, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/allergy-immunology-general" alt="View article keyword Allergy/Immunology General" data-interactiontype="article_recirculation_click">Allergy/Immunology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/autoimmune-disease" alt="View article keyword Autoimmune Disease" data-interactiontype="article_recirculation_click">Autoimmune Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/dermatology-general" alt="View article keyword Dermatology General" data-interactiontype="article_recirculation_click">Dermatology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/inflammatory-disease" alt="View article keyword Inflammatory Disease" data-interactiontype="article_recirculation_click">Inflammatory Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/neuromuscular-disease" alt="View article keyword Neuromuscular Disease" data-interactiontype="article_recirculation_click">Neuromuscular Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/rheumatology-general" alt="View article keyword Rheumatology General" data-interactiontype="article_recirculation_click">Rheumatology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Rohit</span> <span property="familyName">Aggarwal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christina</span> <span property="familyName">Charles-Schoeman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joachim</span> <span property="familyName">Schessl</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zsuzsanna</span> <span property="familyName">Bata-Csörgő</span>, <span property="honorificSuffix">M.D., Dr.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mazen M.</span> <span property="familyName">Dimachkie</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zoltan</span> <span property="familyName">Griger</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sergey</span> <span property="familyName">Moiseev</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chester</span> <span property="familyName">Oddis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Elena</span> <span property="familyName">Schiopu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jiri</span> <span property="familyName">Vencovský</span>, <span property="honorificSuffix">M.D., Dr.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Irene</span> <span property="familyName">Beckmann</span></span>, <span property="author" typeof="Person"><span property="givenName">Elisabeth</span> <span property="familyName">Clodi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Olga</span> <span property="familyName">Bugrova</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Katalin</span> <span property="familyName">Dankó</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Floranne</span> <span property="familyName">Ernste</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Namita A.</span> <span property="familyName">Goyal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marvin</span> <span property="familyName">Heuer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marie</span> <span property="familyName">Hudson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yessar M.</span> <span property="familyName">Hussain</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chafic</span> <span property="familyName">Karam</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nina</span> <span property="familyName">Magnolo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ronald</span> <span property="familyName">Nelson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nataliia</span> <span property="familyName">Pozur</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Liudmyla</span> <span property="familyName">Prystupa</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Miklós</span> <span property="familyName">Sárdy</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Guillermo</span> <span property="familyName">Valenzuela</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anneke J.</span> <span property="familyName">van der Kooi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tuan</span> <span property="familyName">Vu</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0724-0210" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0724-0210</a></span>, <span property="author" typeof="Person"><span property="givenName">Margitta</span> <span property="familyName">Worm</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Todd</span> <span property="familyName">Levine</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the ProDERM Trial Group<sup><a href="#fn2" role="doc-noteref">†</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the University of Pittsburgh School of Medicine, Pittsburgh (R.A., C.O.), and Penn Neuroscience Center–Neurology, Hospital of the University of Pennsylvania, Philadelphia (C.K.) — both in Pennsylvania; the University of California, Los Angeles, Los Angeles (C.C.-S.), and the Department of Neurology, University of California, Irvine, Irvine (N.A.G.); the Friedrich-Baur Institute, Department of Neurology (J.S.), and the Department of Dermatology and Allergy, University Hospital (M.S.), Ludwig-Maximilians University of Munich, Munich, the University Hospital of Münster, Münster (N.M.), and the Clinic for Dermatology, Venereology and Allergology, Charité, Universitätsmedizin Berlin, Berlin (M.W.) — all in Germany; the Department of Dermatology and Allergology, University of Szeged, Szeged (Z.B.-C.), the Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen (Z.G., K.D.), and the Department of Dermatology, Venereology, and Dermatooncology, Semmelweis University, Budapest (M.S.) — all in Hungary; the University of Kansas Medical Center, Kansas City (M.M.D.); the Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow (S.M.), and Orenburg State Medical University, Orenburg (O.B.) — both in Russia; the Division of Rheumatology, Department of Internal Medicine, Michigan Medicine University Hospitals, Ann Arbor (E.S.); the Institute of Rheumatology and the Department of Rheumatology, Charles University, Prague, Czech Republic (J.V.); Octapharma Pharmazeutika, Vienna (I.B., E.C.); the Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN (F.E.); HMD Research, Orlando (M. Heuer), and Integral Rheumatology and Immunology Specialists (IRIS) and IRIS Research and Development, Plantation (G.V.), and the Department of Neurology, University of South Florida, Tampa (T.V.) — all in Florida; the Division of Rheumatology, Department of Medicine, Jewish General Hospital, Lady Davis Institute and McGill University, Montreal (M. Hudson); the University of Texas at Austin Dell Medical School, Austin Neuromuscular Center, Austin (Y.M.H.); Stones River Dermatology, Murfreesboro, TN (R.N.); Ivano-Frankivsk City Clinical Hospital No. 1, Ivano-Frankivsk (N.P.), and the Department of Internal Medicine, Sumy State University, Medical Institute, Sumy (L.P.) — both in Ukraine; the Department of Neurology, Amsterdam University Medical Centers, Amsterdam (A.J.K.); and Phoenix Neurological Associates, Phoenix, AZ (T.L.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Aggarwal can be contacted at <a href="mailto:aggarwalr@upmc.edu">aggarwalr@upmc.edu</a> or at the Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, 3601 Fifth Ave., Suite 2B, Pittsburgh, PA 15213.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">Katalin Dankó, M.D., is deceased.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="fn2" role="paragraph">A full list of the investigators and coinvestigators in the ProDERM Trial Group is provided in the <a href="#ap2">Supplementary Appendix, available at NEJM.org</a>.</div></div><div role="doc-footnote"><div id="fn3" role="paragraph">Drs. Charles-Schoeman and Schessl contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">125</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2117912" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="93532e1a-8c4c-4b1e-9b24-4f81b439ef3f"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136835918" style="display:inline-block;">
                <img alt="Article has an altmetric score of 760" src="https://badges.altmetric.com/?size=320&amp;score=760&amp;types=mmbtttt1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136835918">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_93532e1a-8c4c-4b1e-9b24-4f81b439ef3f" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136835918&amp;tab=news">
          Picked up by <b>91</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136835918&amp;tab=blogs">
          Blogged by <b>4</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136835918&amp;tab=twitter">
          Posted by <b>140</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136835918&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>164</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6edbdf7276260-GRU"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2117912"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-14%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2117912%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="125" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Liza J. McCann, </li><li class="list-inline-item cited-by__entry__author">Andrew L. Mammen, </li><li class="list-inline-item cited-by__entry__author">Lisa G. Rider, </li></ul><span class="cited-by__entry__title">Inflammatory Myopathies, </span><span class="cited-by__entry__series-title">Swaiman's Pediatric Neurology, </span><span class="cited-by__entry__page-range">(1494-1506.e5), </span><span class="cited-by__entry__pub-date">(2026).</span><a href="https://doi.org/10.1016/B978-0-443-10944-7.00171-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/B978-0-443-10944-7.00171-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/B978-0-443-10944-7.00171-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kristen L. Chen, </li><li class="list-inline-item cited-by__entry__author">Yvonne E. Chiu, </li><li class="list-inline-item cited-by__entry__author">Ruth Ann Vleugels, </li><li class="list-inline-item cited-by__entry__author">Dominic O. Co, </li><li class="list-inline-item cited-by__entry__author">Hanna Kim, </li><li class="list-inline-item cited-by__entry__author">Sara E. Sabbagh, </li><li class="list-inline-item cited-by__entry__author">Lisa M. Arkin, </li></ul><span class="cited-by__entry__title">Recent Advances in Juvenile Dermatomyositis: Moving toward Integration of Myositis-Specific Antibody Clinical Phenotypes, IFN-Driven Pathogenesis, and Targeted Therapies, </span><span class="cited-by__entry__series-title">Journal of Investigative Dermatology, </span><span class="cited-by__entry__volume"><strong>145</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1294-1304), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jid.2024.09.017" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jid.2024.09.017</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jid.2024.09.017" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Adalgisa Palermo, </li><li class="list-inline-item cited-by__entry__author">Edoardo Biancalana, </li><li class="list-inline-item cited-by__entry__author">Alessandra Bettiol, </li><li class="list-inline-item cited-by__entry__author">Luisa Brussino, </li><li class="list-inline-item cited-by__entry__author">Corrado Campochiaro, </li><li class="list-inline-item cited-by__entry__author">Valentina Canti, </li><li class="list-inline-item cited-by__entry__author">Marco Capassoni, </li><li class="list-inline-item cited-by__entry__author">Chiara Cardelli, </li><li class="list-inline-item cited-by__entry__author">Linda Carli, </li><li class="list-inline-item cited-by__entry__author">Lorenzo Dagna, </li><li class="list-inline-item cited-by__entry__author">Maria Giovanna Danieli, </li><li class="list-inline-item cited-by__entry__author">Giacomo De Luca, </li><li class="list-inline-item cited-by__entry__author">Serena Guiducci, </li><li class="list-inline-item cited-by__entry__author">Marta Mosca, </li><li class="list-inline-item cited-by__entry__author">Patrizia Rovere-Querini, </li><li class="list-inline-item cited-by__entry__author">Maria Letizia Urban, </li><li class="list-inline-item cited-by__entry__author">Giacomo Emmi, </li><li class="list-inline-item cited-by__entry__author">Gemma Lepri, </li><li class="list-inline-item cited-by__entry__author">Stefania Nicola, </li><li class="list-inline-item cited-by__entry__author">Simone Barsotti, </li><li class="list-inline-item cited-by__entry__author">Denise Menghini, </li><li class="list-inline-item cited-by__entry__author">Cristina Mezzanotte, </li></ul><span class="cited-by__entry__title">Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (hf-SCIg) for inflammatory myositis: a multicenter retrospective real-world observational study, </span><span class="cited-by__entry__series-title">European Journal of Internal Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejim.2025.05.016" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejim.2025.05.016</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejim.2025.05.016" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Emily O Broad, </li></ul><span class="cited-by__entry__title">Rapid Progression of Dermatomyositis in an Elderly Patient With Oropharyngeal and Pulmonary Involvement: A Case Report, </span><span class="cited-by__entry__series-title">Cureus, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7759/cureus.84267" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7759/cureus.84267</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7759/cureus.84267" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Tsuneyasu Yoshida, </li><li class="list-inline-item cited-by__entry__author">Ran Nakashima, </li></ul><span class="cited-by__entry__title">Anti- Melanoma Differentiation-Associated Gene 5 Antibody Positive Dermatomyositis: Recent Progress in Pathophysiology and Treatment, </span><span class="cited-by__entry__series-title">Current Rheumatology Reports, </span><span class="cited-by__entry__volume"><strong>27</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s11926-025-01188-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s11926-025-01188-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s11926-025-01188-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Katherine M. Geric, </li><li class="list-inline-item cited-by__entry__author">Hania S. Khan, </li><li class="list-inline-item cited-by__entry__author">Robert Dazé, </li></ul><span class="cited-by__entry__title">TIF1-gamma associated dermatomyositis with extensive cutaneous involvement, </span><span class="cited-by__entry__series-title">Journal of Osteopathic Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1515/jom-2024-0190" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1515/jom-2024-0190</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1515/jom-2024-0190" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Siamak Moghadam-Kia, </li><li class="list-inline-item cited-by__entry__author">Anushka Aggarwal, </li><li class="list-inline-item cited-by__entry__author">Swamy Venuturupalli, </li><li class="list-inline-item cited-by__entry__author">Shiri Keret, </li><li class="list-inline-item cited-by__entry__author">Nantakarn Pongtarakulpanit, </li><li class="list-inline-item cited-by__entry__author">Mark Riley, </li><li class="list-inline-item cited-by__entry__author">Shalini Mahajan, </li><li class="list-inline-item cited-by__entry__author">Daphne Scaramangas-Plumley, </li><li class="list-inline-item cited-by__entry__author">Aarat Patel, </li><li class="list-inline-item cited-by__entry__author">Joe Kelley, </li><li class="list-inline-item cited-by__entry__author">Eleni Tiniakou, </li><li class="list-inline-item cited-by__entry__author">Chester V Oddis, </li><li class="list-inline-item cited-by__entry__author">Rohit Aggarwal, </li><li class="list-inline-item cited-by__entry__author">Keith Schenberger, </li><li class="list-inline-item cited-by__entry__author">Douglas White, </li><li class="list-inline-item cited-by__entry__author">Micheal Leone, </li><li class="list-inline-item cited-by__entry__author">Teerin Liewluck, </li><li class="list-inline-item cited-by__entry__author">Edward Skol, </li><li class="list-inline-item cited-by__entry__author">Donald Martin, </li><li class="list-inline-item cited-by__entry__author">Carl Henderson, </li><li class="list-inline-item cited-by__entry__author">Jack Vine, </li><li class="list-inline-item cited-by__entry__author">Ronald Bell, </li><li class="list-inline-item cited-by__entry__author">Sheryl Cowan, </li><li class="list-inline-item cited-by__entry__author">Marc Quinn, </li><li class="list-inline-item cited-by__entry__author">Jonathan D Leffert, </li><li class="list-inline-item cited-by__entry__author">Matlock Jefferies (Dianne Cooper), </li><li class="list-inline-item cited-by__entry__author">Surabhi Khanna, </li><li class="list-inline-item cited-by__entry__author">Nishant Gupta, </li><li class="list-inline-item cited-by__entry__author">Lana King, </li><li class="list-inline-item cited-by__entry__author">Raphael Kieval, </li><li class="list-inline-item cited-by__entry__author">Kenneth Crager, </li><li class="list-inline-item cited-by__entry__author">Helene Kramer, </li><li class="list-inline-item cited-by__entry__author">Dennis Ozment, </li><li class="list-inline-item cited-by__entry__author">Jeffrey Callen, </li><li class="list-inline-item cited-by__entry__author">Joe Kelley, </li><li class="list-inline-item cited-by__entry__author">Heather Larabee, </li><li class="list-inline-item cited-by__entry__author">Jeremy Murdock, </li><li class="list-inline-item cited-by__entry__author">Sandra Elizabeth Bendick, </li><li class="list-inline-item cited-by__entry__author">Sarah L Shen, </li><li class="list-inline-item cited-by__entry__author">Anderson -WIlliams, </li><li class="list-inline-item cited-by__entry__author">Janet Kim, </li><li class="list-inline-item cited-by__entry__author">Hayri Sangiray, </li><li class="list-inline-item cited-by__entry__author">Victor Chen, </li><li class="list-inline-item cited-by__entry__author">Louis Flaspohler, </li><li class="list-inline-item cited-by__entry__author">Victoria Werth, </li><li class="list-inline-item cited-by__entry__author">Jemima Albayda, </li><li class="list-inline-item cited-by__entry__author">Joshua Sundhar, </li><li class="list-inline-item cited-by__entry__author">Qaiser Rehman, </li><li class="list-inline-item cited-by__entry__author">Joseph Shanahan, </li><li class="list-inline-item cited-by__entry__author">Georgia Seely, </li><li class="list-inline-item cited-by__entry__author">Yadira Velazquez-Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Sheetal Shroff, </li><li class="list-inline-item cited-by__entry__author">Christine Chhakchhuak, </li><li class="list-inline-item cited-by__entry__author">Jemima Albayda, </li><li class="list-inline-item cited-by__entry__author">Emilia Dulgheru, </li><li class="list-inline-item cited-by__entry__author">Ernest Hoffman, </li><li class="list-inline-item cited-by__entry__author">Shazia Beg, </li><li class="list-inline-item cited-by__entry__author">Daniel Jacobs, </li><li class="list-inline-item cited-by__entry__author">James Curran, </li><li class="list-inline-item cited-by__entry__author">Laurie Mathie, </li><li class="list-inline-item cited-by__entry__author">Michael (Emil) Thelen, </li><li class="list-inline-item cited-by__entry__author">Eleni Tiniakou, </li><li class="list-inline-item cited-by__entry__author">Merrideth Morris, </li><li class="list-inline-item cited-by__entry__author">Kristin D'Silva, </li><li class="list-inline-item cited-by__entry__author">Rory Marks, </li><li class="list-inline-item cited-by__entry__author">Brent Culver, </li><li class="list-inline-item cited-by__entry__author">Ho Bing Oei, </li><li class="list-inline-item cited-by__entry__author">Sharon Nations, </li><li class="list-inline-item cited-by__entry__author">Sarah Coleman, </li><li class="list-inline-item cited-by__entry__author">Brittany Adler, </li><li class="list-inline-item cited-by__entry__author">Carrie Richardson, </li><li class="list-inline-item cited-by__entry__author">M Porter Meadors, </li><li class="list-inline-item cited-by__entry__author">Wai Lee, </li><li class="list-inline-item cited-by__entry__author">Sou-Pan Wu, </li><li class="list-inline-item cited-by__entry__author">Christopher Wright, </li><li class="list-inline-item cited-by__entry__author">Luiziana Manuela Marinescu, </li><li class="list-inline-item cited-by__entry__author">Prahlad Reddy, </li><li class="list-inline-item cited-by__entry__author">Shibu Skaria, </li><li class="list-inline-item cited-by__entry__author">Judy Huang, </li><li class="list-inline-item cited-by__entry__author">Sandra Chesoni, </li><li class="list-inline-item cited-by__entry__author">Marcela Perez, </li><li class="list-inline-item cited-by__entry__author">Naveed Sami, </li><li class="list-inline-item cited-by__entry__author">Rudy Greene, </li><li class="list-inline-item cited-by__entry__author">Ruba Barakat Kado/Elena Schiopu, </li><li class="list-inline-item cited-by__entry__author">Kenneth Crager, </li><li class="list-inline-item cited-by__entry__author">Eric Slavin, </li><li class="list-inline-item cited-by__entry__author">Robert Kalish, </li><li class="list-inline-item cited-by__entry__author">Maya Estephan, </li><li class="list-inline-item cited-by__entry__author">Tina Shah, </li><li class="list-inline-item cited-by__entry__author">Jessica Baer Mears, </li><li class="list-inline-item cited-by__entry__author">Glenn Douglas, </li><li class="list-inline-item cited-by__entry__author">Kara Liane Steijlen, </li><li class="list-inline-item cited-by__entry__author">Kanchana Herath, </li><li class="list-inline-item cited-by__entry__author">Vernon Berglund, </li><li class="list-inline-item cited-by__entry__author">Charles Mills, </li><li class="list-inline-item cited-by__entry__author">Timothy Gensler, </li><li class="list-inline-item cited-by__entry__author">James Wilson, </li><li class="list-inline-item cited-by__entry__author">Kam Newman, </li><li class="list-inline-item cited-by__entry__author">Leo Wang, </li><li class="list-inline-item cited-by__entry__author">Chere McCormick, </li><li class="list-inline-item cited-by__entry__author">Jerrica Farias APRN, </li><li class="list-inline-item cited-by__entry__author">William McCune, </li><li class="list-inline-item cited-by__entry__author">Angela Gierut, </li><li class="list-inline-item cited-by__entry__author">Julie Paik, </li><li class="list-inline-item cited-by__entry__author">Joseph Enama, </li><li class="list-inline-item cited-by__entry__author">Anna Popazoglou, </li><li class="list-inline-item cited-by__entry__author">Ghaith Nosiseh, </li></ul><span class="cited-by__entry__title">Recruitment rate comparison between a virtual tele-research cohort and a traditional centre-based cohort in idiopathic inflammatory myopathy, </span><span class="cited-by__entry__series-title">Rheumatology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/rheumatology/keaf217" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/rheumatology/keaf217</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/rheumatology/keaf217" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ryan Bonaventure Soares, </li><li class="list-inline-item cited-by__entry__author">Jihad Ben Gabr, </li><li class="list-inline-item cited-by__entry__author">Mark Ash, </li><li class="list-inline-item cited-by__entry__author">Gregory Hosler, </li></ul><span class="cited-by__entry__title">Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome, </span><span class="cited-by__entry__series-title">Case Reports in Rheumatology, </span><span class="cited-by__entry__volume"><strong>2025</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1155/crrh/5560523" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1155/crrh/5560523</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1155/crrh/5560523" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Oleg M. Uryas’yev, </li><li class="list-inline-item cited-by__entry__author">Oksana Yu. Lazareva, </li><li class="list-inline-item cited-by__entry__author">Anton V. Shakhanov, </li><li class="list-inline-item cited-by__entry__author">Svetlana V. Berstneva, </li><li class="list-inline-item cited-by__entry__author">Vadim A. Lunyakov, </li><li class="list-inline-item cited-by__entry__author">Kseniya A. Alekseyenkova, </li><li class="list-inline-item cited-by__entry__author">Elena A. Dolzhenkova, </li><li class="list-inline-item cited-by__entry__author">Ekaterina V Ogorel’tseva, </li></ul><span class="cited-by__entry__title">Use of intravenous immunoglobulin in treatment for refractory dermatomyositis: a case report, </span><span class="cited-by__entry__series-title">I.P. Pavlov Russian Medical Biological Herald, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(105-115), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.17816/PAVLOVJ456412" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.17816/PAVLOVJ456412</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.17816/PAVLOVJ456412" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hiroyuki Sakaguchi, </li><li class="list-inline-item cited-by__entry__author">Shigeki Nanjo, </li><li class="list-inline-item cited-by__entry__author">Shigeki Sato, </li><li class="list-inline-item cited-by__entry__author">Hiroshi Kotani, </li><li class="list-inline-item cited-by__entry__author">Akihiro Nishiyama, </li><li class="list-inline-item cited-by__entry__author">Kaname Yamashita, </li><li class="list-inline-item cited-by__entry__author">Koushiro Ohtsubo, </li><li class="list-inline-item cited-by__entry__author">Chiaki Suzuki, </li><li class="list-inline-item cited-by__entry__author">Masaya Shimojima, </li><li class="list-inline-item cited-by__entry__author">Seiji Yano, </li><li class="list-inline-item cited-by__entry__author">Shinji Takeuchi, </li></ul><span class="cited-by__entry__title">Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports, </span><span class="cited-by__entry__series-title">Internal Medicine, </span><span class="cited-by__entry__volume"><strong>64</strong>, </span><span class="cited-by__entry__issue">8, </span><span class="cited-by__entry__page-range">(1205-1210), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.2169/internalmedicine.4162-24" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.2169/internalmedicine.4162-24</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.2169/internalmedicine.4162-24" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-14%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2117912%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2117912" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2117912" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2117912.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f0.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/c2a055d2-4c89-43ea-86ad-832d0543e958/assets/images/large/nejmoa2117912_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f1.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/484bb077-42ee-4171-ba4c-2aec7b1f449f/assets/images/large/nejmoa2117912_f1.jpg" height="2285" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">IVIG denotes intravenous immune globulin.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f2.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/d8e8d215-7dbb-4166-87da-a5b699acd283/assets/images/large/nejmoa2117912_f2.jpg" height="1337" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Total Improvement Score (TIS) at Week 16 and Week 40.</div><div class="notes"><div role="doc-footnote">Shown is the mean TIS up to the end of the double-blind, randomized, placebo-controlled phase at week 16 and up to the end of the open-label extension phase at week 40. The TIS is a weighted composite score reflecting the change over time in a core set of six measures of myositis activity; scores range from 0 to 100, with higher scores indicating greater improvement (see the <a href="#ap2">Supplementary Appendix</a>). Conclusions cannot be drawn from the results from week 16 to week 40 (the open-label extension phase), because these results are descriptive only. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2117912/asset/104a710c-50d4-4795-9eac-5a4a1d760591/assets/images/large/nejmoa2117912_t1.jpg" height="3004" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Characteristics</th><th class="xxxx-borders">IVIG<br>(N=47)</th><th class="xxxx-borders">Placebo<br>(N=48)</th><th class="xxxx-borders">Total<br>(N=95)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">55.0 (22.0–77.0)</td><td class="xxxx-borders shading">51.5 (22.0–79.0)</td><td class="xxxx-borders shading">52.0 (22.0–79.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">36 (77)</td><td class="xxxx-borders">35 (73)</td><td class="xxxx-borders">71 (75)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">44 (94)</td><td class="xxxx-borders">43 (90)</td><td class="xxxx-borders">87 (92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">2 (4)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">1 (1)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Ethnic group — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Hispanic or Latino</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (10)</td><td class="xxxx-borders shading">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Not Hispanic or Latino</td><td class="xxxx-borders">47 (100)</td><td class="xxxx-borders">43 (90)</td><td class="xxxx-borders">90 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Median time since diagnosis (range) — yr</td><td class="xxxx-borders shading">2.4 (0.1–48.7)</td><td class="xxxx-borders shading">2.9 (0.1–18.4)</td><td class="xxxx-borders shading">2.6 (0.1–48.7)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Criteria of Bohan and Peter — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Symmetric proximal muscle weakness</td><td class="xxxx-borders shading">47 (100)</td><td class="xxxx-borders shading">48 (100)</td><td class="xxxx-borders shading">95 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Evidence of myositis on muscle biopsy</td><td class="xxxx-borders">23 (49)</td><td class="xxxx-borders">23 (48)</td><td class="xxxx-borders">46 (48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Elevation of serum skeletal muscle enzymes</td><td class="xxxx-borders shading">43 (91)</td><td class="xxxx-borders shading">44 (92)</td><td class="xxxx-borders shading">87 (92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Electromyographic finding consistent with myositis</td><td class="xxxx-borders">31 (66)</td><td class="xxxx-borders">26 (54)</td><td class="xxxx-borders">57 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Typical skin rash of dermatomyositis</td><td class="xxxx-borders shading">47 (100)</td><td class="xxxx-borders shading">48 (100)</td><td class="xxxx-borders shading">95 (100)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Classification of dermatomyositis according to criteria of Bohan and Peter — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Definite</td><td class="xxxx-borders shading">34 (72)</td><td class="xxxx-borders shading">33 (69)</td><td class="xxxx-borders shading">67 (71)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Probable</td><td class="xxxx-borders">13 (28)</td><td class="xxxx-borders">15 (31)</td><td class="xxxx-borders">28 (29)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Dermatomyositis activity — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Mild</td><td class="xxxx-borders">11 (23)</td><td class="xxxx-borders">15 (31)</td><td class="xxxx-borders">26 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Moderate</td><td class="xxxx-borders shading">29 (62)</td><td class="xxxx-borders shading">27 (56)</td><td class="xxxx-borders shading">56 (59)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Severe</td><td class="xxxx-borders">7 (15)</td><td class="xxxx-borders">6 (12)</td><td class="xxxx-borders">13 (14)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Concomitant medication for dermatomyositis — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Systemic glucocorticoid</td><td class="xxxx-borders">40 (85)</td><td class="xxxx-borders">44 (92)</td><td class="xxxx-borders">84 (88)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Nonglucocorticoid medication</td><td class="xxxx-borders shading">31 (66)</td><td class="xxxx-borders shading">34 (71)</td><td class="xxxx-borders shading">65 (68)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">TIS core-set measures<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Mean MMT-8 score</td><td class="xxxx-borders shading">119.5</td><td class="xxxx-borders shading">122.2</td><td class="xxxx-borders shading">120.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Mean PhGA disease-activity score</td><td class="xxxx-borders">5.13</td><td class="xxxx-borders">4.82</td><td class="xxxx-borders">4.97</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Mean PtGA disease-activity score</td><td class="xxxx-borders shading">5.86</td><td class="xxxx-borders shading">5.79</td><td class="xxxx-borders shading">5.82</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Mean HAQ total score</td><td class="xxxx-borders">1.35</td><td class="xxxx-borders">1.26</td><td class="xxxx-borders">1.31</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Mean extramuscular disease-activity score</td><td class="xxxx-borders shading">4.23</td><td class="xxxx-borders shading">4.17</td><td class="xxxx-borders shading">4.20</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Median muscle enzyme level: creatine kinase — U/liter</td><td class="xxxx-borders">141.0</td><td class="xxxx-borders">113.0</td><td class="xxxx-borders">127.0</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">IVIG denotes intravenous immune globulin.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race and ethnic group were reported by the patient.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"><div class="label">‡</div></a><div id="core-t1fn3" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg">To meet the criteria of Bohan and Peter,<sup></sup></a><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="core-body-ref-r18-2" href-manipulated="true" data-to-manipulate="false">17,18</a> a patient must have a typical skin rash of dermatomyositis in addition to two (for probable dermatomyositis) or at least three (for definite dermatomyositis) of the following four symptoms: symmetric proximal muscle weakness, evidence of myositis on muscle biopsy, elevation of serum skeletal muscle enzyme levels, and electromyographic finding consistent with myositis.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The classification of dermatomyositis activity was based on the physician’s global assessment (PhGA) of disease activity, with a score of 0 to 3 indicating mild disease activity, 4 to 6 moderate disease activity, and 7 to 10 severe disease activity.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Concomitant therapy was allowed provided that the treatment was initiated at least 3 months before enrollment and was continued at a stable dose not exceeding the maximal allowable dose for at least 4 weeks before enrollment.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Scores on the Manual Muscle Test–8 (MMT-8), a measure of strength in eight muscles tested bilaterally, range from 0 to 150, with lower scores indicating weaker muscles. Scores on the PhGA and the patient’s global assessment (PtGA) of disease activity range from 0 (no evidence of disease activity) to 10 (extremely active or severe disease activity). Total scores on the Health Assessment Questionnaire (HAQ) range in increments of 0.125 from 0 (no disability) to 3 (complete disability). Extramuscular disease-activity scores range from 0 to 10, with higher scores reflecting more disease activity in terms of extramuscular organs affected by myositis.</div></div></div></figcaption><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2117912/asset/ce167f1d-2e9d-4c3c-972e-27f6c8afd098/assets/images/large/nejmoa2117912_t2.jpg" height="3438" width="1303" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">IVIG<br>(N=47)</th><th class="txxx-borders">Placebo<br>(N=48)</th><th class="txxr-borders">Difference<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging04 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04" data-xml-align="left">Response at week 16 — % of patients<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">79</td><td class="xxxx-borders">44</td><td class="xxxr-borders">35 (17 to 53)<a href="#core-t2fn3" role="doc-noteref">‡</a><a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading"><b>Secondary end point</b><a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Response according to TIS improvement category at week 16 — % of patients</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">TIS ≥40: at least moderate improvement</td><td class="xxxx-borders shading">68</td><td class="xxxx-borders shading">23</td><td class="xxxr-borders shading">45 (27 to 63)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">TIS ≥60: major improvement</td><td class="xxxx-borders">32</td><td class="xxxx-borders">8</td><td class="xxxr-borders">24 (8 to 39)<a href="#core-t2fn4" role="doc-noteref">§</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Response according to TIS improvement category at week 40 — % of patients<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">TIS ≥20: at least minimal improvement</td><td class="xxxx-borders">71</td><td class="xxxx-borders">70</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">TIS ≥40: at least moderate improvement</td><td class="xxxx-borders shading">58</td><td class="xxxx-borders shading">61</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">TIS ≥60: major improvement</td><td class="xxxx-borders">38</td><td class="xxxx-borders">30</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Modified CDASI<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in total activity score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">−9.4 (−12.5 to −6.2)</td><td class="xxxx-borders shading">−1.2 (−3.3 to 1.0)</td><td class="xxxr-borders shading">−8.0 (−11.5 to −4.6)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Week 16 to week 40</td><td class="xxxx-borders">−1.8 (−3.3 to −0.3)</td><td class="xxxx-borders">−8.5 (−12.5 to −4.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in total damage score (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−0.7 (−1.2 to −0.1)</td><td class="xxxx-borders">−0.02 (−0.26 to 0.21)</td><td class="xxxr-borders">−0.6 (−1.1 to −0.1)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Week 16 to week 40</td><td class="xxxx-borders shading">0.3 (−0.5 to 1.0)</td><td class="xxxx-borders shading">−0.2 (−0.6 to 0.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">SF-36<a href="#core-t2fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in physical component summary score (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">6.3 (3.6 to 9.0)</td><td class="xxxx-borders">2.4 (0.6 to 4.2)</td><td class="xxxr-borders">2.1 (−0.5 to 4.7)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">8.4 (4.3 to 12.6)</td><td class="xxxx-borders shading">6.3 (3.4 to 9.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in mental component summary score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">3.4 (1.1 to 5.6)</td><td class="xxxx-borders shading">2.0 (−0.4 to 4.3)</td><td class="xxxr-borders shading">1.4 (−1.2 to 4.1)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">4.8 (1.5 to 8.2)</td><td class="xxxx-borders">7.4 (3.9 to 10.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Individual core measures of the TIS</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in MMT-8 score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">14.4 (10.0 to 18.8)</td><td class="xxxx-borders shading">3.2 (0.3 to 6.1)</td><td class="xxxr-borders shading">8.6 (4.4 to 12.8)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">20.1 (15.0 to 25.2)</td><td class="xxxx-borders">12.0 (9.4 to 14.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in disease-activity score (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging24 shading">PhGA</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−2.4 (−3.0 to −1.8)</td><td class="xxxx-borders">−0.60 (−1.15 to −0.04)</td><td class="xxxr-borders">−1.4 (−2.1 to −0.8)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">−3.1 (−3.7 to −2.4)</td><td class="xxxx-borders shading">−2.9 (−3.6 to −2.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging24">PtGA</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">−2.2 (−2.9 to −1.5)</td><td class="xxxx-borders shading">−1.1 (−1.8 to −0.5)</td><td class="xxxr-borders shading">−1.0 (−1.8 to −0.1)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">−2.7 (−3.7 to −1.8)</td><td class="xxxx-borders">−2.8 (−3.5 to −2.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change (95% CI) in HAQ total score</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−0.6 (−0.7 to −0.4)</td><td class="xxxx-borders">−0.2 (−0.3 to −0.1)</td><td class="xxxr-borders">−0.4 (−0.5 to −0.2)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">−0.7 (−0.9 to −0.4)</td><td class="xxxx-borders shading">−0.5 (−0.7 to −0.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Mean change in extramuscular disease-activity score (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">−2.2 (−2.8 to −1.5)</td><td class="xxxx-borders shading">−0.9 (−1.7 to −0.2)</td><td class="xxxr-borders shading">−1.2 (−1.9 to −0.5)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">−2.7 (−3.4 to −2.0)</td><td class="xxxx-borders">−2.6 (−3.4 to −1.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Mean change in creatine kinase level (95% CI) — U/liter<a href="#core-t2fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">−169.2 (−301.2 to −37.2)</td><td class="xxxx-borders">−352.8 (−1011.9 to 306.3)</td><td class="xxxr-borders">−80.3 (−213.4 to 52.9)<a href="#core-t2fn8" role="doc-noteref">††</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">−169.4 (−326.1 to −12.7)</td><td class="xxxx-borders shading">−56.5 (−247.9 to 134.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">TIS<a href="#core-t2fn11" role="doc-noteref">¶¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Week 4</td><td class="xxxx-borders shading">24.4±20.8</td><td class="xxxx-borders shading">10.7±13.7</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Week 8</td><td class="xxxx-borders">36.4±21.1</td><td class="xxxx-borders">15.8±20.4</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Week 12</td><td class="xxxx-borders shading">43.4±21.9</td><td class="xxxx-borders shading">18.5±20.2</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Week 16</td><td class="xxxx-borders">48.4±24.4</td><td class="xxxx-borders">21.6±20.2</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Week 28</td><td class="xxxx-borders shading">54.0±20.0</td><td class="xxxx-borders shading">44.4±22.0</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Week 40</td><td class="xxxx-borders">55.4±21.7</td><td class="xxxx-borders">51.1±18.3</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Median time to improvement in TIS (95% CI) — days</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">At least minimal improvement</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">35 (29 to 58)</td><td class="xxxx-borders shading">115 (84 to NC)<a href="#core-t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">35 (29 to 58)</td><td class="xxxx-borders">114 (84 to 195)</td><td class="xxxr-borders">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">At least moderate improvement</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders">85 (58 to 113)</td><td class="xxxx-borders">NC (NC to NC)<a href="#core-t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders shading">85 (58 to 113)</td><td class="xxxx-borders shading">197 (195 to 282)</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Major improvement</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Baseline to week 16</td><td class="xxxx-borders shading">NC (115 to NC)<a href="#core-t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxx-borders shading">NC (NC to NC)<a href="#core-t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Baseline to week 40</td><td class="xxxx-borders">283 (197 to 290)</td><td class="xxxx-borders">283 (203 to NC)<a href="#core-t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging04 shading" data-xml-align="left">Median time to confirmed clinical deterioration in placebo-controlled phase and overall period (95% CI) — days</td><td class="xxxx-borders shading">NC<a href="#core-t2fn13" role="doc-noteref">***</a></td><td class="xxxx-borders shading">NC<a href="#core-t2fn13" role="doc-noteref">***</a></td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging04" data-xml-align="left">Patients meeting criteria for clinical deterioration up to week 16 — no. (%)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">3 (6)</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Week 16 was the end of the double-blind, randomized, placebo-controlled phase of the trial, and week 40 was the end of the open-label extension phase. All patients received IVIG during the open-label extension phase. NA denotes not applicable, and NC not calculated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">A response was defined as a Total Improvement Score (TIS) of at least 20, indicating at least minimal improvement, at week 16. The TIS is a weighted composite score reflecting the change in a core set of six measures of myositis activity over time; scores range from 0 to 100, with higher scores indicating greater improvement from baseline (a TIS of ≥40 indicates at least moderate improvement, and a TIS of ≥60 indicates major improvement).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">P&lt;0.001 by the Cochran–Mantel–Haenszel test.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The between-group difference is expressed in percentage points.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">The widths of the 95% confidence intervals for the secondary end points have not been adjusted for multiple comparisons, and no inferences can be drawn from these data.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Improvement at week 40 was assessed among 45 patients in the IVIG group and among 46 patients in the placebo group. Conclusions cannot be drawn from the results from week 16 to week 40 (the open-label extension phase), because these results are descriptive only.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t2fn7" role="paragraph" data-to-manipulate="true">The modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) total activity score ranges from 0 to 100, and the CDASI total damage score ranges from 0 to 32; higher scores indicate worse disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t2fn8" role="paragraph" data-to-manipulate="true">Data are the least-squares mean difference (95% confidence interval) between IVIG and placebo at week 16.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t2fn9" role="paragraph" data-to-manipulate="true">Physical and Mental Component Summary scores on the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) range from 0 to 100, with higher scores indicating better health status.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="core-t2fn10" role="paragraph" data-to-manipulate="true">No notable changes were observed in the levels of other muscle enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and aldolase).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="core-t2fn11" role="paragraph" data-to-manipulate="true">Data on the TIS were available for 45 patients in the IVIG group and for 48 patients in the placebo group at week 4. The corresponding values for the subsequent assessment weeks were 45 and 47 at week 8; 45 and 46 at week 12; 45 and 43 at week 16; 37 and 40 at week 28; and 34 and 35 at week 40.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖‖</div><div id="core-t2fn12" role="paragraph" data-to-manipulate="true">NC in this cell indicates that the median time to improvement or the lower or upper limit of the 95% confidence interval was not calculated with the use of the LIFETEST procedure in the SAS statistical package (SAS Institute) because the percentage of patients with the event was too low.</div></div><div role="doc-footnote" data-has="label"><div class="label">***</div><div id="core-t2fn13" role="paragraph" data-to-manipulate="true">NC in this cell indicates that the median time to confirmed clinical deterioration was not calculated with the use of the LIFETEST procedure because the percentage of patients with the event was too low.</div></div></div></figcaption></a><figcaption><div class="caption">Results of Primary and Secondary Efficacy End-Point Analyses.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2117912/asset/3acf58d8-7c48-4c6d-8300-33445439b081/assets/images/large/nejmoa2117912_t3.jpg" height="2073" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="2"><span>Randomized,<br>Placebo-Controlled Phase</span></th><th class="txxr-borders">Randomized and Open-Label Extension Phases</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">IVIG<br>(N=52)</th><th class="xxxx-borders">Placebo<br>(N=48)</th><th class="xxxr-borders">IVIG<br>(N=95)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any related adverse event — % of patients (no. of events)</td><td class="xxxx-borders shading">58 (113)</td><td class="xxxx-borders shading">23 (38)</td><td class="xxxr-borders shading">65 (282)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Most frequent related adverse event occurring in ≥5% of patients — % of patients</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">6</td><td class="xxxr-borders shading">42</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">19</td><td class="xxxx-borders">6</td><td class="xxxr-borders">19</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">4</td><td class="xxxr-borders shading">16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0</td><td class="xxxr-borders">8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chills</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">2</td><td class="xxxr-borders shading">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Myalgia</td><td class="xxxx-borders">6</td><td class="xxxx-borders">0</td><td class="xxxr-borders">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">6</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Positive Coombs’ test</td><td class="xxxx-borders">4</td><td class="xxxx-borders">0</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious related nonthromboembolic adverse event — no. of patients/no. of events</td><td class="xxxx-borders shading">1/2</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2/3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Muscle spasm</td><td class="xxxx-borders">1/1<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1<a href="#core-t3fn1" role="doc-noteref">*</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dyspnea</td><td class="xxxx-borders shading">1/1<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1<a href="#core-t3fn1" role="doc-noteref">*</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Loss of consciousness</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious related thromboembolic adverse event — no. of patients/no. of events</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">5/6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Deep-vein thrombosis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1<a href="#core-t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pulmonary embolism</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1<a href="#core-t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cerebrovascular accident</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cerebral infarction</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypoesthesia</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pulmonary embolism</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1/1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Related adverse events leading to discontinuation — % of patients (no. of events)</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">8 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Fatal adverse events — no. of events</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Muscle spasm and dyspnea were two concurrent events in 1 patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Deep-vein thrombosis and pulmonary embolism were two concurrent events in 1 patient and thus were counted as one thromboembolic adverse event.</div></div></div></figcaption></a><figcaption><div class="caption">Incidence of Adverse Events That Were Considered to Be Related to the Trial Regimen during the Placebo-Controlled and Extension Phases.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2117912_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2117912</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Dalakas MC. Inflammatory muscle diseases. <em>N Engl J Med</em> 2015;372:1734-1747.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJMra1402225&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25923553/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000353655000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inflammatory+muscle+diseases.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1734-1747&amp;doi=10.1056%2FNEJMra1402225&amp;pmid=25923553" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disorder of unknown pathogenesis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] predominantly in proximal muscles. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Oddis CV, Aggarwal R. Treatment in myositis. <em>Nat Rev Rheumatol</em> 2018;14:279-289.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrrheum.2018.42" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29593343/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430747200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+in+myositis.&amp;publication_year=2018&amp;journal=Nat+Rev+Rheumatol&amp;pages=279-289&amp;doi=10.1038%2Fnrrheum.2018.42&amp;pmid=29593343" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. <em>Autoimmun Rev</em> 2009;9:124-127.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.autrev.2009.04.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19386287/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272277100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+immunoglobulin+as+add+on+treatment+with+mycophenolate+mofetil+in+severe+myositis.&amp;publication_year=2009&amp;journal=Autoimmun+Rev&amp;pages=124-127&amp;doi=10.1016%2Fj.autrev.2009.04.003&amp;pmid=19386287" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] combination with immunosuppressive drugs, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Ho C, Visintini S. Off-label use of intravenous immunoglobulin for dermatological conditions: a review of clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health, April 20, 2018 (<a href="https://www.cadth.ca/sites/default/files/pdf/htis/2018/RC0965%20-%20Off-label%20IVIG%20Final.pdf">https://www.cadth.ca/sites/default/files/pdf/htis/2018/RC0965%20-%20Off-label%20IVIG%20Final.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Off-label+use+of+intravenous+immunoglobulin+for+dermatological+conditions%3A+a+review+of+clinical+effectiveness&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. <em>Eur J Neurol</em> 2008;15:893-908.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-1331.2008.02246.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18796075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258355900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EFNS+guidelines+for+the+use+of+intravenous+immunoglobulin+in+treatment+of+neurological+diseases%3A+EFNS+task+force+on+the+use+of+intravenous+immunoglobulin+in+treatment+of+neurological+diseases.&amp;publication_year=2008&amp;journal=Eur+J+Neurol&amp;pages=893-908&amp;doi=10.1111%2Fj.1468-1331.2008.02246.x&amp;pmid=18796075" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. <em>Eur J Dermatol</em> 2009;19:90-98.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1684/ejd.2008.0580" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19171549/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263100300031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+on+the+use+of+high-dose+intravenous+immunoglobulin+in+dermatology.&amp;publication_year=2009&amp;journal=Eur+J+Dermatol&amp;pages=90-98&amp;doi=10.1684%2Fejd.2008.0580&amp;pmid=19171549" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. <em>Am J Med</em> 1991;91:162-168.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0002-9343(91)90009-M" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1714235/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1991GB07200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+intravenous+gammaglobulin+therapy+in+chronic+refractory+polymyositis+and+dermatomyositis%3A+an+open+study+with+20+adult+patients.&amp;publication_year=1991&amp;journal=Am+J+Med&amp;pages=162-168&amp;doi=10.1016%2F0002-9343%2891%2990009-M&amp;pmid=1714235" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. <em>J Neurol Neurosurg Psychiatry</em> 1998;65:107-110.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp.65.1.107" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9667570/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000074643100018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immunoglobulin+therapy+in+inflammatory+myopathies.&amp;publication_year=1998&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=107-110&amp;doi=10.1136%2Fjnnp.65.1.107&amp;pmid=9667570" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. <em>Mod Rheumatol</em> 2008;18:34-44.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/s10165-007-0013-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18217197/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000264090600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+high-dose+intravenous+immunoglobulin+therapy+in+Japanese+patients+with+steroid-resistant+polymyositis+and+dermatomyositis.&amp;publication_year=2008&amp;journal=Mod+Rheumatol&amp;pages=34-44&amp;doi=10.3109%2Fs10165-007-0013-0&amp;pmid=18217197" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] IVIG reduces symptoms of dermatomyositis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. <em>N Engl J Med</em> 1993;329:1993-2000.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM199312303292704&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8247075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1993MN57300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+high-dose+intravenous+immune+globulin+infusions+as+treatment+for+dermatomyositis.&amp;publication_year=1993&amp;journal=N+Engl+J+Med&amp;pages=1993-2000&amp;doi=10.1056%2FNEJM199312303292704&amp;pmid=8247075" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in the treatment of dermatomyositis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] evidence of efficacy and safety. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and reduced neuromuscular symptoms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. <em>Blood Coagul Fibrinolysis</em> 2005;16:313-318.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/01.mbc.0000172694.85233.a8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15970713/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000231054300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Venous+and+arterial+thrombosis+following+administration+of+intravenous+immunoglobulins.&amp;publication_year=2005&amp;journal=Blood+Coagul+Fibrinolysis&amp;pages=313-318&amp;doi=10.1097%2F01.mbc.0000172694.85233.a8&amp;pmid=15970713" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Marie I, Maurey G, Hervé F, Hellot M-F, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature. <em>Br J Dermatol</em> 2006;155:714-721.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2133.2006.07390.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16965420/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240348900010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+immunoglobulin-associated+arterial+and+venous+thrombosis%3A+report+of+a+series+and+review+of+the+literature.&amp;publication_year=2006&amp;journal=Br+J+Dermatol&amp;pages=714-721&amp;doi=10.1111%2Fj.1365-2133.2006.07390.x&amp;pmid=16965420" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. <em>Expert Opin Drug Saf</em> 2010;9:971-979.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1517/14740338.2010.484419" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20408737/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282970700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+of+intravenous+immunoglobulin+treatment.&amp;publication_year=2010&amp;journal=Expert+Opin+Drug+Saf&amp;pages=971-979&amp;doi=10.1517%2F14740338.2010.484419&amp;pmid=20408737" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Kapoor M, Hunt I, Spillane J, et al. IVIg-exposure and thromboembolic event risk: findings from the UK Biobank. <em>J Neurol Neurosurg Psychiatry</em> 2022;93:876-885.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2022-328881" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35688633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000810553900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IVIg-exposure+and+thromboembolic+event+risk%3A+findings+from+the+UK+Biobank.&amp;publication_year=2022&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=876-885&amp;doi=10.1136%2Fjnnp-2022-328881&amp;pmid=35688633" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] been associated with thromboembolic events. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of thrombosis associated with IVIG infusion </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and treatment with IVIG </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Chandra T, Aggarwal R. Clinical trials and novel therapeutics in dermatomyositis. <em>Expert Opin Emerg Drugs</em> 2020;25:213-228.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/14728214.2020.1787985" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32597690/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000547133100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+trials+and+novel+therapeutics+in+dermatomyositis.&amp;publication_year=2020&amp;journal=Expert+Opin+Emerg+Drugs&amp;pages=213-228&amp;doi=10.1080%2F14728214.2020.1787985&amp;pmid=32597690" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”). <em>Medicine (Baltimore)</em> 2021;100(1):e23677-e23677.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MD.0000000000023677" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33429735/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000612794500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prospective%2C+double-blind%2C+randomized%2C+placebo-controlled+phase+III+study+evaluating+efficacy+and+safety+of+octagam+10%25+in+patients+with+dermatomyositis+%28%E2%80%9CProDERM+Study%E2%80%9D%29.&amp;publication_year=2021&amp;journal=Medicine+%28Baltimore%29&amp;pages=e23677-e23677&amp;doi=10.1097%2FMD.0000000000023677&amp;pmid=33429735" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] design have been previously published, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were eligible for the trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] or after week 8 at two consecutive visits, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] scores indicating greater improvement. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Bohan A, Peter JB. Polymyositis and dermatomyositis — (second of two parts). <em>N Engl J Med</em> 1975;292:403-407.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM197502202920807&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1089199/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1975V574800007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Polymyositis+and+dermatomyositis+%E2%80%94+%28second+of+two+parts%29.&amp;publication_year=1975&amp;journal=N+Engl+J+Med&amp;pages=403-407&amp;doi=10.1056%2FNEJM197502202920807&amp;pmid=1089199" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to the criteria of Bohan and Peter, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r17-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] To meet the criteria of Bohan and Peter, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Bohan A, Peter JB. Polymyositis and dermatomyositis — (first of two parts). <em>N Engl J Med</em> 1975;292:344-347.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM197502132920706&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1090839/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1975V510400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Polymyositis+and+dermatomyositis+%E2%80%94+%28first+of+two+parts%29.&amp;publication_year=1975&amp;journal=N+Engl+J+Med&amp;pages=344-347&amp;doi=10.1056%2FNEJM197502132920706&amp;pmid=1090839" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to the criteria of Bohan and Peter, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r18-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] To meet the criteria of Bohan and Peter, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. <em>Arthritis Rheum</em> 2004;50:2281-2290.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.20349" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15248228/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+consensus+on+preliminary+definitions+of+improvement+in+adult+and+juvenile+myositis.&amp;publication_year=2004&amp;journal=Arthritis+Rheum&amp;pages=2281-2290&amp;doi=10.1002%2Fart.20349&amp;pmid=15248228" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for use in the evaluation of myositis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] neurologists, and dermatologists. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Rider LG, Aggarwal R, Machado PM, et al. Update on outcome assessment in myositis. <em>Nat Rev Rheumatol</em> 2018;14:303-318.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrrheum.2018.33" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29651119/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430747200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+outcome+assessment+in+myositis.&amp;publication_year=2018&amp;journal=Nat+Rev+Rheumatol&amp;pages=303-318&amp;doi=10.1038%2Fnrrheum.2018.33&amp;pmid=29651119" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. <em>Rheumatology (Oxford)</em> 2001;40:1262-1273.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/40.11.1262" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11709610/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000172378500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Proposed+preliminary+core+set+measures+for+disease+outcome+assessment+in+adult+and+juvenile+idiopathic+inflammatory+myopathies.&amp;publication_year=2001&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1262-1273&amp;doi=10.1093%2Frheumatology%2F40.11.1262&amp;pmid=11709610" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. <em>Arthritis Rheum</em> 2013;65:314-324.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.37754" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23124935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000314169400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+in+the+treatment+of+refractory+adult+and+juvenile+dermatomyositis+and+adult+polymyositis%3A+a+randomized%2C+placebo-phase+trial.&amp;publication_year=2013&amp;journal=Arthritis+Rheum&amp;pages=314-324&amp;doi=10.1002%2Fart.37754&amp;pmid=23124935" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Selva-O’Callaghan A, Fernández-Luque A, Martínez-Gómez X, Labirua-Iturburu A, Vilardell-Tarrés M. Venous thromboembolism in patients with dermatomyositis and polymyositis. <em>Clin Exp Rheumatol</em> 2011;29:846-849.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21962007/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297192600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Venous+thromboembolism+in+patients+with+dermatomyositis+and+polymyositis.&amp;publication_year=2011&amp;journal=Clin+Exp+Rheumatol&amp;pages=846-849&amp;pmid=21962007" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Antovic A, Notarnicola A, Svensson J, Lundberg IE, Holmqvist M. Venous thromboembolic events in idiopathic inflammatory myopathy: occurrence and relation to disease onset. <em>Arthritis Care Res (Hoboken)</em> 2018;70:1849-1855.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.23560" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29579357/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451429400017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Venous+thromboembolic+events+in+idiopathic+inflammatory+myopathy%3A+occurrence+and+relation+to+disease+onset.&amp;publication_year=2018&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=1849-1855&amp;doi=10.1002%2Facr.23560&amp;pmid=29579357" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. <em>Ann Rheum Dis</em> 2016;75:110-116.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2014-205800" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25193998/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366402400011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+deep+venous+thrombosis+and+pulmonary+embolism+in+individuals+with+polymyositis+and+dermatomyositis%3A+a+general+population-based+study.&amp;publication_year=2016&amp;journal=Ann+Rheum+Dis&amp;pages=110-116&amp;doi=10.1136%2Fannrheumdis-2014-205800&amp;pmid=25193998" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Chung W-S, Lin C-L, Sung F-C, Lu C-C, Kao C-H. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. <em>Thromb Res</em> 2014;134:622-626.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r26-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.thromres.2014.06.021" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25034321/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341310000018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+risk+of+venous+thromboembolism+in+patients+with+dermatomyositis%2Fpolymyositis%3A+a+nationwide+cohort+study.&amp;publication_year=2014&amp;journal=Thromb+Res&amp;pages=622-626&amp;doi=10.1016%2Fj.thromres.2014.06.021&amp;pmid=25034321" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r26-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] processes and decreased mobility, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and increased inflammatory processes) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] are risk factors for thromboembolic events, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/paediatric rheumatology international trials organisation collaborative initiative. <em>Arthritis Rheumatol</em> 2017;69:898-910.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40064" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28382787/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2016+American+College+of+Rheumatology%2FEuropean+League+Against+Rheumatism+criteria+for+minimal%2C+moderate%2C+and+major+clinical+response+in+adult+dermatomyositis+and+polymyositis%3A+an+international+myositis+assessment+and+clinical+studies+group%2Fpaediatric+rheumatology+international+trials+organisation+collaborative+initiative.&amp;publication_year=2017&amp;journal=Arthritis+Rheumatol&amp;pages=898-910&amp;doi=10.1002%2Fart.40064&amp;pmid=28382787" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for adult dermatomyositis and polymyositis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] neurologists, and dermatologists. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <em>Arthritis Rheumatol</em> 2017;69:2271-2282.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40320" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29106061/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2017+European+League+Against+Rheumatism%2FAmerican+College+of+Rheumatology+classification+criteria+for+adult+and+juvenile+idiopathic+inflammatory+myopathies+and+their+major+subgroups.&amp;publication_year=2017&amp;journal=Arthritis+Rheumatol&amp;pages=2271-2282&amp;doi=10.1002%2Fart.40320&amp;pmid=29106061" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. <em>Mod Rheumatol</em> 2012;22:382-393.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/s10165-011-0534-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21971943/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000305275300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+intravenous+immunoglobulin+therapy+in+Japanese+patients+with+polymyositis+and+dermatomyositis+resistant+to+corticosteroids%3A+a+randomized+double-blind+placebo-controlled+trial.&amp;publication_year=2012&amp;journal=Mod+Rheumatol&amp;pages=382-393&amp;doi=10.3109%2Fs10165-011-0534-4&amp;pmid=21971943" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] evidence of efficacy and safety. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the IVIG group and placebo group. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. <em>J Clin Immunol</em> 2014;34:Suppl 1:S120-S126.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10875-014-0024-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24722854/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanistic+effects+of+IVIg+in+neuroinflammatory+diseases%3A+conclusions+based+on+clinicopathologic+correlations.&amp;publication_year=2014&amp;journal=J+Clin+Immunol&amp;pages=S120-S126&amp;doi=10.1007%2Fs10875-014-0024-5&amp;pmid=24722854" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r31-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] formation of the membrane attack complex. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] down-regulation of cytokines and chemokines </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. <em>Curr Rheumatol Rep</em> 2011;13:192-198.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r31-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11926-011-0171-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21503696/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000208771200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanisms+of+action+of+intravenous+immunoglobulin+in+inflammatory+muscle+disease.&amp;publication_year=2011&amp;journal=Curr+Rheumatol+Rep&amp;pages=192-198&amp;doi=10.1007%2Fs11926-011-0171-0&amp;pmid=21503696" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r31-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r31-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] formation of the membrane attack complex. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and modification of gene expression </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Basta M, Van Goor F, Luccioli S, et al. F(ab)’2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. <em>Nat Med</em> 2003;9:431-438.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm836" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12612546/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000181987400033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=F%28ab%29%E2%80%992-mediated+neutralization+of+C3a+and+C5a+anaphylatoxins%3A+a+novel+effector+function+of+immunoglobulins.&amp;publication_year=2003&amp;journal=Nat+Med&amp;pages=431-438&amp;doi=10.1038%2Fnm836&amp;pmid=12612546" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. <em>J Clin Invest</em> 1994;94:1729-1735.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI117520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7962520/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PQ94100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High-dose+intravenous+immunoglobulin+exerts+its+beneficial+effect+in+patients+with+dermatomyositis+by+blocking+endomysial+deposition+of+activated+complement+fragments.&amp;publication_year=1994&amp;journal=J+Clin+Invest&amp;pages=1729-1735&amp;doi=10.1172%2FJCI117520&amp;pmid=7962520" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. <em>Ann Neurol</em> 1990;27:343-356.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.410270402" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2353792/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1990CZ77200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Microvascular+changes+in+early+and+advanced+dermatomyositis%3A+a+quantitative+study.&amp;publication_year=1990&amp;journal=Ann+Neurol&amp;pages=343-356&amp;doi=10.1002%2Fana.410270402&amp;pmid=2353792" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. <em>N Engl J Med</em> 1986;314:329-334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_36_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2117912&amp;key=10.1056%2FNEJM198602063140601&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/3945256/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1986AYS4600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Microvascular+deposition+of+complement+membrane+attack+complex+in+dermatomyositis.&amp;publication_year=1986&amp;journal=N+Engl+J+Med&amp;pages=329-334&amp;doi=10.1056%2FNEJM198602063140601&amp;pmid=3945256" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <em>Arthritis Care Res (Hoboken)</em> 2010;62:1533-1541.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20280" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20583105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000284041200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+Paediatric+Rheumatology+International+Trials+Organisation+provisional+criteria+for+the+evaluation+of+response+to+therapy+in+juvenile+dermatomyositis.&amp;publication_year=2010&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=1533-1541&amp;doi=10.1002%2Facr.20280&amp;pmid=20583105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Rider LG, Giannini EH, Harris-Love M, et al. Defining clinical improvement in adult and juvenile myositis. <em>J Rheumatol</em> 2003;30:603-617.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12610824/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+clinical+improvement+in+adult+and+juvenile+myositis.&amp;publication_year=2003&amp;journal=J+Rheumatol&amp;pages=603-617&amp;pmid=12610824" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. <em>Rheumatology (Oxford)</em> 2021;60:1784-1792.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keaa459" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33099648/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000644544400040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravenous+immunoglobulins+as+first-line+treatment+in+idiopathic+inflammatory+myopathies%3A+a+pilot+study.&amp;publication_year=2021&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1784-1792&amp;doi=10.1093%2Frheumatology%2Fkeaa459&amp;pmid=33099648" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. <em>Arthritis Rheumatol</em> 2021;73:858-865.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41602" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33258553/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Study+of+tofacitinib+in+refractory+dermatomyositis%3A+an+open-label+pilot+study+of+ten+patients.&amp;publication_year=2021&amp;journal=Arthritis+Rheumatol&amp;pages=858-865&amp;doi=10.1002%2Fart.41602&amp;pmid=33258553" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 05, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2209117" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Intravenous Immune Globulin Therapy in Dermatomyositis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.A. Amato</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 04, 2023</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2214285" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trial of Intravenous Immune Globulin in Dermatomyositis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> New Hyde Park, New York</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/715653/pediatric-hospitalists-cohen-children-s-medical-center/?query=fjwp&amp;rid=3059">Pediatric Hospitalists - Cohen Children's Medical Center</a></div></div><div class="nejm-widget_item"><div><span> Dayton, Ohio</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881334/anesthesiologist-hospital-based-dayton-oh-630-000-/?query=fjwp&amp;rid=74242">Anesthesiologist - Hospital-Based (Dayton, OH) - $630,000+ </a></div></div><div class="nejm-widget_item"><div><span> Newport News, Virginia</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887373/pediatric-hospitalist/?query=fjwf&amp;rid=49812">Pediatric Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Nashville, Tennessee</span></div><div><span>Pediatrics, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886147/pediatric-newborn-hospitalist-per-diem-/?query=fjwf&amp;rid=49812">Pediatric/Newborn Hospitalist (Per Diem)</a></div></div><div class="nejm-widget_item"><div><span> Yuba City, California</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881888/physician-radiology-yuba-city-ca-/?query=fjwf&amp;rid=845681">Physician, Radiology (Yuba City, CA)</a></div></div><div class="nejm-widget_item"><div><span> Boston, Massachusetts</span></div><div><span>Ophthalmology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880197/comprehensive-ophthalmologist/?query=fjwf&amp;rid=427770">Comprehensive Ophthalmologist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2117912&amp;pubId=41283475&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6edbdf7276260-GRU">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6edbdf7276260-GRU"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6edbdf7276260-GRU"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$751507825$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$751507825$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$751507825$--></div></div><div class="mlt-body"><!--?lit$751507825$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$751507825$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$751507825$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$751507825$-->Aug 01, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312302?query=recirc_Semantic" target="_self">Brief Report: Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease</a></div><div class="mlt-article-authors"><!--?lit$751507825$-->H. Griffin and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/images-in-clinical-medicine" target="_self"><!--?lit$751507825$-->Images in Clinical Medicine</a> <span class="mlt-article-site-label"><!--?lit$751507825$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$751507825$-->Jun 24, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMicm2033425?query=recirc_Semantic" target="_self">Dermatomyositis</a></div><div class="mlt-article-authors"><!--?lit$751507825$-->K.A. O’Connell and A.H. LaChance</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$751507825$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$751507825$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$751507825$-->Aug 08, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2314466?query=recirc_Semantic" target="_self">Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn</a></div><div class="mlt-article-authors"><!--?lit$751507825$-->K.J. Moise, Jr., and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$751507825$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$751507825$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$751507825$-->Jul 01, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2108276?query=recirc_Semantic" target="_self">Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics</a></div><div class="mlt-article-authors"><!--?lit$751507825$-->R.L. DeBiasi</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$751507825$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$751507825$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$751507825$-->Apr 24, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2312718?query=recirc_Semantic" target="_self">Neonatal Fc Receptor — Biology and Therapeutics</a></div><div class="mlt-article-authors"><!--?lit$751507825$-->J.B. Bussel, D.B. Cines, and R.S. Blumberg</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2117912?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2117912" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2117912.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2117912"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Trial of Intravenous Immune Globulin in Dermatomyositis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2204961" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2208343" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>A Bivalent Omicron-Containing Booster Vaccine against Covid-19</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f0.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/c2a055d2-4c89-43ea-86ad-832d0543e958/assets/images/large/nejmoa2117912_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f1.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/484bb077-42ee-4171-ba4c-2aec7b1f449f/assets/images/large/nejmoa2117912_f1.jpg" height="2285" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">IVIG denotes intravenous immune globulin.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2117912_f2.jpg"><img src="/cms/10.1056/NEJMoa2117912/asset/d8e8d215-7dbb-4166-87da-a5b699acd283/assets/images/large/nejmoa2117912_f2.jpg" height="1337" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Total Improvement Score (TIS) at Week 16 and Week 40.</div><div class="notes"><div role="doc-footnote">Shown is the mean TIS up to the end of the double-blind, randomized, placebo-controlled phase at week 16 and up to the end of the open-label extension phase at week 40. The TIS is a weighted composite score reflecting the change over time in a core set of six measures of myositis activity; scores range from 0 to 100, with higher scores indicating greater improvement (see the <a href="#ap2">Supplementary Appendix</a>). Conclusions cannot be drawn from the results from week 16 to week 40 (the open-label extension phase), because these results are descriptive only. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Results of Primary and Secondary Efficacy End-Point Analyses.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Incidence of Adverse Events That Were Considered to Be Related to the Trial Regimen during the Placebo-Controlled and Extension Phases.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/14" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 14</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 06, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2208343" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Bivalent Omicron-Containing Booster Vaccine against Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S. Chalkias and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 06, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2206485" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Efficacy and Safety of an Extravascular Implantable Cardioverter–Defibrillator</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Friedman and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 06, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2204961" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.R. Kapadia and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2117912%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2117912&amp;pubId=41283475&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2117912%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2117912&amp;pubId=41283475&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id08776435972211689" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6edbdf7276260-GRU" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6edbdf7276260-GRU" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6edbdf7276260-GRU"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6edbdf7276260-GRU"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6edbdf7276260-GRU"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6edbdf7276260-GRU"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6edbdf7276260-GRU">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6edbdf7276260-GRU">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6edbdf7276260-GRU"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6edbdf7276260-GRU"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6edbde9726260',t:'MTc0OTUzODE2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6edbde9726260&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-transactionid="djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" id="captureIFrame_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" target="captureIFrame_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="capture_screen"><input id="capture_signIn_js_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="js_version"><input id="capture_signIn_transactionId_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" type="hidden" class="capture_transactionId_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="capture_transactionId"><input id="capture_signIn_form_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="form"><input id="capture_signIn_flow_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="flow"><input id="capture_signIn_client_id_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="client_id"><input id="capture_signIn_redirect_uri_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="redirect_uri"><input id="capture_signIn_response_type_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="response_type"><input id="capture_signIn_flow_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="flow_version"><input id="capture_signIn_settings_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="settings_version"><input id="capture_signIn_locale_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="locale"><input id="capture_signIn_recaptcha_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_djsh0ksp2yo5bvt7pik90iozpw0494fsxuemj83v" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><goa-pblgatsnoyew></goa-pblgatsnoyew><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2117912?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script></body></html>